US20220325264A1 - Modified nucleic acid editing systems for tethering donor dna - Google Patents
Modified nucleic acid editing systems for tethering donor dna Download PDFInfo
- Publication number
- US20220325264A1 US20220325264A1 US17/531,450 US202117531450A US2022325264A1 US 20220325264 A1 US20220325264 A1 US 20220325264A1 US 202117531450 A US202117531450 A US 202117531450A US 2022325264 A1 US2022325264 A1 US 2022325264A1
- Authority
- US
- United States
- Prior art keywords
- dna
- nucleic acid
- sequence
- composition
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 125
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 110
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 110
- 108020004414 DNA Proteins 0.000 claims abstract description 135
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 101710163270 Nuclease Proteins 0.000 claims abstract description 47
- 230000004568 DNA-binding Effects 0.000 claims abstract description 34
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 32
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 32
- 108091035707 Consensus sequence Proteins 0.000 claims abstract description 23
- 230000027455 binding Effects 0.000 claims abstract description 22
- 108091033409 CRISPR Proteins 0.000 claims description 88
- 239000013598 vector Substances 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 56
- 108020005004 Guide RNA Proteins 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 238000010459 TALEN Methods 0.000 claims description 20
- 108010054278 Lac Repressors Proteins 0.000 claims description 15
- 230000002950 deficient Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 108010001515 Galectin 4 Proteins 0.000 claims description 8
- 102100039556 Galectin-4 Human genes 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 5
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 4
- 108020005202 Viral DNA Proteins 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 108091029865 Exogenous DNA Proteins 0.000 claims description 3
- 108050004197 Trp repressor Proteins 0.000 claims description 3
- 230000030648 nucleus localization Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 69
- -1 guide sequences Substances 0.000 description 41
- 238000010362 genome editing Methods 0.000 description 40
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 29
- 239000008101 lactose Substances 0.000 description 29
- 239000012634 fragment Substances 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 27
- 230000004927 fusion Effects 0.000 description 24
- 230000004048 modification Effects 0.000 description 24
- 238000012986 modification Methods 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 19
- 239000004098 Tetracycline Substances 0.000 description 18
- 235000019364 tetracycline Nutrition 0.000 description 18
- 229960002180 tetracycline Drugs 0.000 description 18
- 229930101283 tetracycline Natural products 0.000 description 18
- 150000003522 tetracyclines Chemical class 0.000 description 18
- 101150109249 lacI gene Proteins 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 238000001890 transfection Methods 0.000 description 17
- 238000010276 construction Methods 0.000 description 16
- 239000013603 viral vector Substances 0.000 description 16
- 230000035772 mutation Effects 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 12
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 11
- 230000005782 double-strand break Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000010363 gene targeting Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 9
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 8
- 108091092356 cellular DNA Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000002105 nanoparticle Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 7
- 101150029409 CFTR gene Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 239000013607 AAV vector Substances 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 108010034634 Repressor Proteins Proteins 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 102000009661 Repressor Proteins Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000006780 non-homologous end joining Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 229920001432 poly(L-lactide) Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 3
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229910002056 binary alloy Inorganic materials 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 101150024821 tetO gene Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 2
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- QXDXBKZJFLRLCM-UAKXSSHOSA-N 5-hydroxyuridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(O)=C1 QXDXBKZJFLRLCM-UAKXSSHOSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920005689 PLLA-PGA Polymers 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002597 lactoses Chemical class 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MPDKOGQMQLSNOF-GBNDHIKLSA-N 2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidin-6-one Chemical compound O=C1NC(N)=NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPDKOGQMQLSNOF-GBNDHIKLSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- LZWSGWMPCIAGIJ-UAKXSSHOSA-N 4,5-diamino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C(N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LZWSGWMPCIAGIJ-UAKXSSHOSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- MPPUDRFYDKDPBN-UAKXSSHOSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxypyrimidin-2-one Chemical compound C1=C(O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPPUDRFYDKDPBN-UAKXSSHOSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- SKRPUDFNLCXIOY-ZEQWWUPGSA-N 5-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxypyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1(O)C(=O)NC(=O)N=C1 SKRPUDFNLCXIOY-ZEQWWUPGSA-N 0.000 description 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 1
- HITGTSFRKOQULY-DKZDHXMOSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound CC1([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=NC(=O)NC1=O HITGTSFRKOQULY-DKZDHXMOSA-N 0.000 description 1
- YBTWWWIJBCCYNR-UAKXSSHOSA-N 5-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YBTWWWIJBCCYNR-UAKXSSHOSA-N 0.000 description 1
- QOVIBFFZCVPCEI-UMMCILCDSA-N 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QOVIBFFZCVPCEI-UMMCILCDSA-N 0.000 description 1
- TUZRSOLHFXTHNA-ZEQWWUPGSA-N 5-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound NC1([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=NC(=O)NC1=O TUZRSOLHFXTHNA-ZEQWWUPGSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- OZTOEARQSSIFOG-MWKIOEHESA-N 6-Thio-7-deaza-8-azaguanosine Chemical compound Nc1nc(=S)c2cnn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1 OZTOEARQSSIFOG-MWKIOEHESA-N 0.000 description 1
- CBNRZZNSRJQZNT-IOSLPCCCSA-O 6-thio-7-deaza-guanosine Chemical compound CC1=C[NH+]([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C(NC(N)=N2)=C1C2=S CBNRZZNSRJQZNT-IOSLPCCCSA-O 0.000 description 1
- MJJUWOIBPREHRU-MWKIOEHESA-N 7-Deaza-8-azaguanosine Chemical compound NC=1NC(C2=C(N=1)N(N=C2)[C@H]1[C@H](O)[C@H](O)[C@H](O1)CO)=O MJJUWOIBPREHRU-MWKIOEHESA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 description 1
- 101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000010442 DNA editing Methods 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100326871 Escherichia coli (strain K12) ygbF gene Proteins 0.000 description 1
- 101100438439 Escherichia coli (strain K12) ygbT gene Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Chemical group 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101100368144 Mus musculus Synb gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- TWOFBVMVSYSAFW-UFUGHDFUSA-N N'-(3-aminopropyl)butane-1,4-diamine (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol guanidine Chemical compound NC(N)=N.NC(N)=N.NCCCCNCCCN.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 TWOFBVMVSYSAFW-UFUGHDFUSA-N 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- LZCNWAXLJWBRJE-ZOQUXTDFSA-N N4-Methylcytidine Chemical compound O=C1N=C(NC)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LZCNWAXLJWBRJE-ZOQUXTDFSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 229920001257 Poly(D,L-lactide-co-PEO-co-D,L-lactide) Polymers 0.000 description 1
- 229920001267 Poly(D,L-lactide-co-PPO-co-D,L-lactide) Polymers 0.000 description 1
- 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101100329497 Thermoproteus tenax (strain ATCC 35583 / DSM 2078 / JCM 9277 / NBRC 100435 / Kra 1) cas2 gene Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710175714 Tyrosine aminotransferase Proteins 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 101150000705 cas1 gene Proteins 0.000 description 1
- 101150117416 cas2 gene Proteins 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 1
- 229920001253 poly(D,L-lactide-co-caprolactone-co-glycolide) Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001279 poly(ester amides) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 229920000575 polymersome Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940096913 pseudoisocytidine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 101150003509 tag gene Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Definitions
- the technology relates to compositions for tethering donor DNA to a nuclease the use of those compositions for improving the efficiency of in vivo gene editing.
- TALENs Transcription Activator-Like Effector Nucleases
- CRISPR-Cas9 system Clustered, Regularly Interspaced, Short Palindromic Repeats and CRISPR associated protein 9
- ZFNs Zinc finger nucleases
- TALENs, CRISPR-Cas9 protein and ZFNs use endonucleases to initiate double-strand breaks (DSBs) at almost any target sequence in genomic DNA and can be used for gene knockouts, gene knock-ins, gene tagging, and correction of genetic defects.
- CRISPR type II bacterial clustered, regularly interspaced, short palindromic repeats
- Cas9-associated protein 9 Cas9
- RNAs stimulate Cas9-mediated double stranded breaks (DSBs) at desired target sites in cellular DNA while minimizing effects at other locations.
- Double stranded breaks stimulate DNA repair by at least two distinct mechanisms non-homologous end joining (NHEJ) and homology directed repair (HDR).
- NHEJ non-homologous end joining
- HDR homology directed repair
- Cas9-mediated modification of cellular DNA by NHEJ can reach efficiencies of 20-60% but because NHEJ is error-prone and introduces unpredictable patterns of insertions and deletions it is only suitable for introducing small random mutations.
- Co-application CRISPR-Cas9 with a single-stranded or double-stranded DNA template homologous to the sequences flanking the cleavage site on the cellular DNA enables precise genome editing by HDR-mediated incorporation of an exogenous, or donor DNA fragment.
- the frequency of HDR is inherently low and the efficiency of insertion of a donor DNA using this strategy is only 0.5-20%.
- TALENs are fusions of transcription activator-like (TAL) proteins and a Fok I nuclease.
- TAL proteins are typically composed of 33-34 amino acid repeating motifs with two variable positions that have a strong recognition for specific nucleotide sequences. By assembling arrays of TALs and fusing them to a Fok I nuclease, specific cutting of the genome can be achieved. When two TALENs bind and meet, the Fok I domains induce a double-strand break which can inactivate a gene, or can be used to insert DNA of interest. TALENs are able to modify chromosomes with efficiency of up to about 33%.
- ZFNs are a class of engineered DNA-binding proteins that allow targeted genome editing of the genome by creating double-strand breaks in DNA at desired locations.
- ZFNs consist of two functional domains, a DNA-binding domain comprised of a chain of Zinc-finger modules, each recognizing a unique DNA hexamer. Multiple Zinc-fingers can be assembled to form ZFN with specificity for a sequence of 24 bases or more.
- the second functional domain is the nuclease domain of Fok I. Using ZFNs can result in single or biallelic edits occurring at an efficiency of 1-20% of clone population.
- the present inventor has developed compositions and methods that utilise the target specificity of gene editing systems such as CRISPR-Cas9, TALENs and ZFNs to tether a donor DNA to a desired target DNA sequence.
- composition comprising a composition for tethering donor DNA to a nuclease, the composition comprising a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of:
- a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence
- nucleic acid encoding the fusion protein a nucleic acid encoding the fusion protein.
- the nuclease may be a Cas, a Transcription activator-like effector nuclease (TALEN), a meganuclease, or a Zinc Finger.
- TALEN Transcription activator-like effector nuclease
- the fusion protein may further comprises a nuclear localization sequence.
- composition may further comprise a guide RNA that interacts with the Cas protein and a target DNA sequence.
- the consensus sequence may comprise the Lac operator (SEQ ID NO: 66), the TRP operator (SEQ ID NO: 68), the TET operator (SEQ ID NO: 67), the GAL-4 binding site (SEQ ID NO: 1), or the IHF binding site (SEQ ID NO 2).
- the consensus sequence may comprise a sequence with at least 80%, 85%, 90%, 95% or at least 99% identity to the Lac operator, the TRP operator, the TET operator, the GAL-4 binding site, or the IHF binding site
- the DNA biding domain may comprises the LAC repressor, TET repressor, TRP-repressor, GAL-4, or IHF, or a portion thereof sufficient to bind the consensus sequence.
- the DNA binding domain is the LAC repressor, preferably amino acids 43-403 of SEQ ID NO 9.
- the nuclease may be coupled to the DNA binding domain via a linker.
- the linker may comprise a sequence selected from any one of SEQ ID Nos: 3 to 7, a GGS linker, or amino acids 404-419 of SEQ ID NO 9.
- the fusion protein comprises the LAC repressor and Cas9.
- composition may comprise a vector, wherein the vector comprises either or both of:
- nucleic acid comprising the donor DNA and the consensus sequence for a DNA binding domain
- the vector may further comprise a nucleic acid sequence encoding a guide RNA that interacts with the Cas9 and a target DNA sequence.
- the fusion protein is nuclease deficient.
- an isolated host cell comprising the composition of the first aspect.
- a method for editing DNA in a cell comprising;
- composition of the first aspect under conditions suitable for the interaction of the fusion protein with a target DNA sequence.
- a method for editing DNA in a cell comprising
- nucleic acid editing system adapted to edit the genomic DNA at a second target DNA sequence, under conditions suitable for nucleic acid editing.
- the target DNA sequence may be selected from genomic DNA, mitochondrial DNA, viral DNA, or exogenous DNA.
- the efficiency of editing is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 99%.
- the cell may be in a subject, preferably a human subject.
- a kit comprising:
- nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of
- the fusion protein in the kit comprises a Cas protein, a Transcription activator-like effector nuclease (TALEN), a meganuclease, a Zinc Finger or a MADzyme.
- TALEN Transcription activator-like effector nuclease
- the Cas is Cas9.
- FIG. 1 is a depiction of two embodiments of the composition disclosed herein comprising a modified nucleic acid editing system.
- FIG. 2 is a map of a plasmid vector containing an active Cas 9 gene sequence and its guide RNA capable of directing binding of the Crispr/Cas9 complex to a genomic target DNA sequence, donor DNA sequence that can be used for repair of Crispr/Cas9 induced double strand breaks.
- FIG. 3 is a map of a plasmid used in a binary system where the Crispr/Cas9 gene sequence containing the lac repressor fusion and guide RNA are present on a tether expression vector and the donor DNA sequence is present on a second tethered gene targeting vector.
- FIG. 4 is a map of a plasmid used in a binary system where the Crispr/Cas9 gene sequence containing the lac repressor fusion and guide RNA are present on a tether expression vector and the donor DNA sequence is present on a second tethered gene targeting vector.
- FIG. 5 is a map of a plasmid for generating an in vitro system whereby purified Crispr/Cas9 would is used to bind a gene targeting vector prior to transfection into cells.
- FIG. 6 is a map of a plasmid for generating an in vitro system whereby purified Crispr/Cas9 would is used to bind a gene targeting vector prior to transfection into cells.
- FIG. 7 is a workflow diagram for construction of an in vivo tethered gene-targeting plasmid, where A represents the synthesis of U6 expression cassette containing Ug promoter with a central SspI recognition sequence and flanking SspI compatible overhangs that do not reconstruct the plasmid SspI recognition sequence.
- B represents the synthesis of CMV promoter-SV40-polyA cassette containing central NotI cloning site and Eco109I compatible overhangs.
- C represents Synthesis of gene encoding Cas9-lac repressor fusion protein with NotI compatible overhangs.
- D represents synthesis of gene encoding RNA complementary to genomic target DNA sequence with SspI compatible overhangs.
- E represent PCR amplification of donor DNA sequence with oligonucleotide containing flanking SaII restriction endonuclease recognition sequences and digestions with SaII.
- FIG. 8A is a workflow diagram for the construction of pGT1. Construction of lactose repressor gene with inactivated BbsI restriction endonuclease sites.
- FIG. 8B is a workflow diagram for the construction of pGT1.
- FIG. 8C is a workflow diagram for the construction of pGT1. Three overlapping DNA fragments comprising Flag/SV40 NLS, lacI and Cas9 were made, and these were cloned into pSpCas9 BB-2A-GFP(px458).
- FIG. 8D is a vector map if pGT1.
- FIG. 9 is a vector map of the ptet repressor plasmid used in the construction of pGT9.
- FIG. 10A is a workflow diagram for the construction of pGT9.
- a tet repressor cassette was cloned into pUC57 to create ptet repressor.
- FIG. 10B is a workflow diagram for the construction of pGT9. Three polymerase chain reaction products, Flag/SV40 NLS, lacI and Cas9, were generated.
- FIG. 10C is a workflow diagram for the construction of pGT9.
- Three polymerase chain reaction products, Flag/SV40 NLS, lacI and Cas9 were cloned into pSpCas9 BB-2A-GFP(px458).
- FIG. 10D is a vector map of pGT9.
- FIG. 11 is an overview of a donor fragment, showing a 500 pase pair donor fragment with deIF508 Mutation and lacO or tetO Recognition Sequences
- FIG. 12 is an overview of the use of the compositions described herein for homology directed repair by homologous recombination between the genomic CFTR target Cas9-induced double strand break and donor fragment to catalyze transfer of the deIF508 DNA sequence to the genomic target.
- FIG. 13 illustrates that combination of pGT1 vector (lactose repressor-Cas9 fusion) with the 130117 guide (genomic target forward strand) and lactose operator on the 3′ end of donor DNA ( FIG. 13 , lane 7) demonstrates higher gene editing efficiency as compared to the px458 vector with unmodified Cas9 and same donor DNA fragment
- FIG. 14 illustrates that gene editing with the pGT9 tetracycline repressor-Cas9 fusion vector, guide sequences, and donor fragments did not yield appreciably better gene editing frequencies than the control px458 vector
- the present disclosure provides compositions, methods, and kits for tethering donor DNA to a DNA target sequence with a modified nucleic acid editing system.
- the disclosure provides for improved efficiency of in vivo cellular DNA modification (such as gene editing) using a modified nucleic acid editing system, such as CRISPR-Cas9.
- a modified nucleic acid editing system such as CRISPR-Cas9.
- FIG. 1 One embodiment of this process is illustrated in FIG. 1 .
- the modified gene editing system is adapted a bind to a nucleic acid comprising donor DNA and tether the nucleic acid to a specific site on the cellular DNA at or near to the nucleotide sequence to be edited.
- compositions and methods described herein can include a nuclease of any nucleic acid editing system capable of site specific binding.
- useful nucleases include Cas nucleases, TALENs, meganucleases, ZFNs and MADzymes.
- the nuclease is modified by combining it with a DNA binding domain.
- linker The nuclease and the DNA binding domain may be joined via linker.
- Suitable linkers include for example, linkers comprising the sequences (Gly-Gly-Gly-Gly-Ser) n , (Gly) n , or (Gly) n S, (EAAAK) n , (AP) n , (XP) n , or A(EAAAK) n where n is any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 and X is any amino acid.
- linkers comprise the sequences KESGSVSSEQLAQFRSLD, EGKSSGSGSESKST, GSAGSAAGSGEF, KESGSVSSEQLAQFRSLE, or GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG.
- Cas systems are divided into three major types (type I, type II, and type III) and twelve subtypes, which are based on their genetic content and structural differences.
- the core defining features of all CRISPR-Cas systems are the Cas genes and their proteins: cas1 and cas2 are universal across types and subtypes, while Cas3, Cas9, and Cas10 are signature genes for type I, type II, and type III, respectively.
- any Cas may be used.
- the Cas nuclease may be Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10.
- the Cas is Cas9.
- Cas9 (CRISPR associated protein 9) is an RNA-guided DNA nuclease used to induce site-directed double strand breaks in DNA for the gene inactivation or the introduction of heterologous genes through non-homologous end joining and homologous recombination respectively.
- Systems and nucleic acids sequences for expressing Cas9 are commercially available.
- the Cas9 may be codon optimized for a human or other mammalian system.
- the Cas9 protein may contain a nuclear localization signal at the C-terminus.
- the RNA encoding Cas9 may be capped and polyadenylated to support expression in mammalian cells, and may contain modifications to reduce immune stimulation.
- the amino acid sequence and encoding nucleic acid sequence for Cas9 and functional derivatives and homologs which can be used in the compositions and methods are known in the art.
- the Cas9 may be delivered in conjunction with a guide RNA (gRNA) that directs the editing system to the nucleotide sequence recognized by the gRNA.
- gRNA guide RNA
- a gRNA can be designed to target any nucleotide sequence.
- the gRNA structure is disclosed in, for example, Ran F A, Genome editing using the CRISPR-Cas9 System. PNAS 8(1 1):2281-308 (2013); and Pyzocha et al., RNA-guided genome editing of mammalian cells. Methods Mol. Biol. 1 1 14:269-77 (2014), which are hereby incorporated by reference in their entirety.
- gRNAs guide the Cas9 to the complementary 20 nucleotide sequences with a downstream NGG protospacer-adjacent motif (PAM).
- PAM NGG protospacer-adjacent motif
- CRISPR-Cas9 In place of a CRISPR-Cas9 system, alternate nucleic acid editing systems may be used.
- suitable systems include any CRISPR/cas system (e.g., any Cascade-like CRISPR/cas, Type I CRISPR cas, Type II CRISPR/cas, and type III CRISPR/cas), zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, homing endonucleases, and MADzymes (for examples the Human or E. coli MADzymes encoded by SEQ ID Nos: 69 and 70, respectively.
- CRISPR/cas system e.g., any Cascade-like CRISPR/cas, Type I CRISPR cas, Type II CRISPR/cas, and type III CRISPR/cas
- ZFNs zinc finger nucleases
- TALENs transcription activator-like effector nucleases
- MADzymes for examples the Human
- the DNA binding domain component of the modified nucleic acid editing system can be any sequence specific high affinity DNA binding domain.
- the term ‘DNA binding domain’ as used herein refers to any complete protein or fragment thereof which can bind DNA. Accordingly the term ‘DNA binding domain’ includes complete proteins such as the LAC repressor and fragments of the protein which retain the DNA binding
- the DNA binding domain is not mammalian in order to reduce of target effects.
- the DNA binding domain may be from a bacteria or yeast.
- DNA binding domains useful in the compositions and methods described herein can be selected from the group consisting of be the LAC repressor, TET repressor, TRP-repressor, GAL-4, or IHF. Each of these bind specific consensus sequences that are known in the art.
- the consensus sequence may be the Lac operator (e.g. SEQ ID NO: 66), the TRP operator (e.g. SEQ ID NO: 68), the TET operator (e.g. SEQ ID NO: 67), the GAL-4 binding site (5′-CGG-N 11 -CCG-3′) or the IHF binding site (5′-WATCAANNNNTTR-3′).
- W is A or T
- R is A or G
- N is any nucleotide.
- the nucleic acid editing systems can be present in the compositions disclosed herein in the form of purified proteins or in the form of nucleic acids encoding the nucleic acid editing system.
- the nucleic acid may be a vector, for example a plasmid vector comprising sequences encoding the nucleic acid editing system operably linked to a constitutive or inducible promoter.
- vector includes a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes.
- Certain exemplary vectors may be plasmids, lentiviruses or adeno-associated viruses.
- Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
- vector refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
- viral vector wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses).
- Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g.
- bacterial vectors having a bacterial origin of replication and episomal mammalian vectors.
- Other vectors e.g., non-episomal mammalian vectors
- certain vectors are expression vectors capable of directing the expression of genes to which they are operatively linked. Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- Recombinant expression vectors can comprise one or more nucleic acids encoding a modified nucleic acid editing system in a form suitable for expression of the nucleic acid in a cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression. That is the regulatory elements are operatively-linked to the nucleic acid sequence to be expressed. ‘Operably linked’ means that that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- Regulatory element includes promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory elements are known in the art. Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes).
- tissue-specific regulatory sequences may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes).
- a vector may comprise one or more poI Ill promoter (e.g. 1, 2, 3, 4, 5, or more poI III promoters), one or more poI H promoters (e.g. 1, 2, 3, 4, 5, or more poI H promoters), one or more poI I promoters (e.g. 1, 2, 3, 4, 5, or more poI 1 promoters), or combinations thereof.
- poI III promoters include, but are not limited to, U6 and HI promoters.
- poI II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer), the SV40 promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphoglycerol Kinase (PGK) promoter, and the EFIa promoter and Poi H promoters described herein.
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- SV40 promoter the dihydrofolate reductase promoter
- ⁇ -actin promoter the phosphoglycerol Kinase (PGK) promoter
- EFIa promoter and Poi H promoters described herein include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhance
- enhancer elements such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-1; SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin.
- WPRE Wideband RNA
- CMV enhancers CMV enhancers
- R-U5′ segment in LTR of HTLV-1 CMV enhancers
- SV40 enhancer SV40 enhancer
- the intron sequence between exons 2 and 3 of rabbit ⁇ -globin can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc.
- a vector can be introduced into host cells to thereby produce transcripts (e.g. guide RNA), proteins, or peptides, including fusion proteins (such as the modified nucleic acid editing systems) or peptides.
- the vector may include one or more terminator sequences.
- a terminator sequence includes a section of nucleic acid sequence that marks the end of a coding sequence during transcription.
- the vector may include one or more sequences encoding an epitope tag or reporter gene sequences.
- epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemaglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
- reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HAP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and auto-fluorescent proteins including blue fluorescent protein (BFP).
- GST glutathione-S-transferase
- HAP horseradish peroxidase
- CAT chloramphenicol acetyltransferase
- beta-galactosidase betaglucuronidase
- luciferase green fluorescent protein
- GFP green fluorescent protein
- HcRed HcRed
- DsRed cyan fluorescent protein
- YFP yellow fluorescent protein
- BFP auto-fluorescent proteins including blue fluorescent protein
- compositions may comprise a mRNA encoding the fusion protein.
- the mRNA can be modified, and the modification selected from one or more of modifications of the phosphate backbone (e.g., phosphorothioate linkages or boranophosphate linkages), ribose ring modifications such as 2′-0-methyl and/or 2′-fluoro and/or 4′-thio modifications, and locked or unlocked nucleic acids.
- modifications of the phosphate backbone e.g., phosphorothioate linkages or boranophosphate linkages
- ribose ring modifications such as 2′-0-methyl and/or 2′-fluoro and/or 4′-thio modifications
- locked or unlocked nucleic acids e.g., locked or unlocked nucleic acids.
- Other modifications may include pseudouridine, 2-thiouridine, 4-thiouridine, 5-azauridine, 5-hydroxyuridine, 5-aminouridine, 5-methyluridine, 2-thiopseudouridine, 4-thiopseudouridine, 5-hydroxypseudouridine, 5-methylpseudouridine, 5-aminopseudouridine, pseudoisocytidine, 5-methylcytidine, N4-methylcytidine, 2-thiocytidine, 5-azacytidine, 5-hydroxycytidine, 5-aminocytidine, N4-methylpseudoisocytidine, 2-thiopseudoisocytidine, 5-hydroxypseudoisocytidine, 5-aminopseudoisocytidine, 5-methylpseudoisocytidine, N6-methyladenosine, 7-deazaadenosine, 6-thioguanosine, 7-deazaguanosine, 8-azaguanos
- the modifications are selected for one or more of the following: reduce immune stimulation, RNA stabilization, improve expression of the encoded protein.
- the RNA may have a combination of 2-thiouridine and 5-methyl-cytidine to reduce immune stimulation through pattern recognition receptors such as TLR3, TLR7 and TLR8.
- the mRNA has one or more pseudouridine to stabilize the mRNA against cleavage, and improve expression rates.
- the modified nucleic acid editing systems also comprise a DNA binding domain.
- the DNA binding domain facilitates the localisation of the modified nucleic acid editing system to cellular DNA.
- Construction of the vectors disclosed herein is by standard methods known in the art such as ligation of synthetic nucleic acids, or nucleic acids produced by, for example PCR, into a plasmid that has been cut by one or more site-specific nucleases.
- the entire vector(s) are synthesized de novo using a commercially available service, for example by a company that emphasizes in the synthesis of large DNA molecules.
- Modification of Cas9-lac repressor fusion proteins to add other DNA binding domains or epitopes for affinity purification of modified Cas9 proteins can be performed by recombinant PCR followed by ligation into restriction endonuclease sites in the vector backbone.
- a workflow illustrating this process for preparing the plasmid vectors disclosed herein is shown in FIG. 7 .
- the nucleic acid editing system is nuclease deficient.
- the nuclease deficient nucleic acid editing system is used to tether the donor DNA near to a target nucleic acid sequence so that donor DNA is available for use by an additional nucleic acid editing system.
- nuclease deficient gene editing system has reduced or eliminated nuclease activity, alternatively the nuclease activity is absent or substantially absent within levels of detection.
- nuclease activity of the gene editing system may be undetectable using known assays, i.e. below the level of detection of known assays.
- Nuclease deficient gene editing systems can be prepared by those skilled in the art using standard molecular biology techniques. Typically this involves deleting or altering one or more amino acids crucial for nuclease activity to substantially eliminate or eliminate nuclease activity.
- the Cas9 is a nuclease-deficient Cas9.
- a nuclease-deficient Cas9 may be one in which one or more amino acids in Cas9 are altered or removed.
- a nuclease deficient Cas9 may be generated by removing or mutating one or more of the amino acids D10, H840, D839 and N863 (See Jinke et al., Science 337, 816-821 (2012).
- one or more of these amino acids may be deleted or substituted with alanine or glycine to substantially eliminates or eliminates nuclease activity.
- donor DNA includes a nucleic acid sequence which is to be inserted into cellular DNA (such as of genomic DNA, mitochondrial DNA, or viral DNA).
- the donor nucleic acid sequence may be expressed by the cell.
- the donor nucleic can be exogenous, foreign to the cell or non-naturally occurring within the cell.
- the donor DNA is associated with a sequence that can be bound by a DNA binding domain.
- the donor DNA may be contiguous with a consensus sequence for a DNA binding domain or may be present on the same vector as the a consensus sequence, or may be present on the same polynucleotide as the consensus sequence.
- a target nucleic acid sequence includes any nucleic acid sequence, such as a genomic nucleic acid sequence or a gene to which a nuclease of a nucleic acid editing system can co-localise.
- Target nucleic acids include nucleic acid sequences capable of being expressed into proteins.
- the target nucleic acid is genomic DNA, mitochondrial DNA, plastid DNA, viral DNA, or exogenous DNA.
- RNAs TALENs
- ZFNs TALENs
- meganucleases homing endonucleases which co-localize to a target nucleic acid sequence.
- compositions and vectors described herein can be used in for editing DNA in a cell.
- the methods comprise contacting the cell with a composition comprising a modified gene editing system or vector encoding a modified gene editing system under conditions suitable for the interaction of the modified nucleic acid editing system with a target DNA sequence.
- the methods also comprise use of a nuclease-deficient modified nucleic acid editing system that interacts with a first target DNA sequence and a conventional nucleic acid editing system to edit the DNA at a second target DNA sequence.
- the donor DNA is positioned close to the target DNA sequence so that it is readily available for nucleic acid editing.
- nuclease-deficient modified nucleic acid editing system this is achieved by spacing the first and second target sequences so that the donor DNA is closed to the conventional nucleic acid editing system when it is colocalised with its target sequence.
- the first and second target sequences are about 75 to 150 base pairs apart, about 150-250, 250-350, 450-550, 550-650, 650-750, 750-850, 850-950, 950-1050 base pairs apart or about 1-1.5 kb apart.
- the methods require delivery of the compositions or vectors to the cell.
- Methods of non-viral delivery of nucleic acid vectors, RNA or proteins include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, agent-enhanced uptake of DNA, nanoparticles, and electroporation/nucleofection.
- Lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides are known. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
- the term native includes the protein, enzyme, RNA, or guide RNA species itself as well as the corresponding nucleic acid encoding the same.
- Delivery vehicles for the compositions and vectors disclosed herein provided herein may be viral vectors or non-viral vectors.
- the modified nucleic acid editing system is provided in a viral vector or a non-viral vector.
- the guide RNA is provided in a viral vector, and the modified nucleic acid editing system is provided in a non-viral vector.
- the guide RNA is provided in a non-viral vector and the modified nucleic acid editing system is provided in a viral vector
- the viral vector is selected from an adeno-associated virus (AAV), adenovirus, retrovirus, and lentivirus vector. While the viral vector may deliver any component of the system described herein so long as it provides the desired profile for tissue presence or expression, in some embodiments the viral vector provides for expression of one or more of the modified nucleic acid editing system, guide RNA and optionally the delivers the donor DNA. In some embodiments, the viral delivery system is adeno-associated virus (AAV) 2/8. However, in various embodiments other AAV serotypes are used, such as AAV1, AAV2, AAV4, AAV5, AAV6, and AAV8.
- AAV adeno-associated virus
- AAV6 is used when targeting airway epithelial cells
- AAV7 is used when targeting skeletal muscle cells (similarly for AAV1 and AAV5)
- AAV8 is used for hepatocytes.
- AAV1 and 5 can be used for delivery to vascular endothelial cells.
- most AAV serotypes show neuronal tropism, while AAV5 also transduces astrocytes.
- hybrid AAV vectors are employed.
- each serotype is administered only once to avoid immunogenicity. Thus, subsequent administrations employ different AAV serotypes.
- the delivery system comprises a non-viral delivery vehicle.
- the non-viral delivery vehicle is lipid-based.
- the non-viral delivery vehicle is a polymer.
- the non-viral delivery vehicle is biodegradable.
- the non-viral delivery vehicle is a lipid encapsulation system and/or polymeric particle.
- the delivery system comprises lipid particles.
- the lipid-based vector is a lipid nanoparticle, which is a lipid particle between about 1 and about 100 nanometers in size.
- the lipid-based vector is a lipid or liposome. Liposomes are artificial spherical vesicles comprising a lipid bilayer.
- the lipid-based vector can be a small nucleic acid-lipid particle (SNALP).
- SNALPs comprise small (less than 200 nm in diameter) lipid-based nanoparticles that encapsulate a nucleic acid.
- the SNALP is useful for delivery of an RNA molecule.
- SNALP formulations deliver nucleic acids to a particular tissue in a subject, such as the liver.
- the guide RNA, the modified nucleic acid editing system (or the RNA encoding the same) is delivered via polymeric vectors.
- the polymeric vector is a polymer or polymerosome.
- Polymers encompass any long repeating chain of monomers and include, for example, linear polymers, branched polymers, dendrimers, and polysaccharides. Linear polymers comprise a single line of monomers, whereas branched polymers include side chains of monomers. Dendrimers are also branched molecules, which are arranged symmetrically around the core of the molecule.
- Polysaccharides are polymeric carbohydrate molecules, and are made up of long monosaccharide units linked together.
- Polymersomes are artificial vesicles made up of synthetic amphiphilic copolymers that form a vesicle membrane, and may have a hollow or aqueous core within the vesicle membrane.
- polymeric materials include poly(D,L-lactic acid-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), PLGA-b-poly(ethylene glycol)-PLGA (PLGA-bPEG-PLGA), PLLA-bPEG-PLLA, PLGA-PEG-maleimide (PLGA-PEG-mal), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L,L-lactide-co-caprolactone-co-glycolide), poly(D,L
- Polymer-based systems may also include Cyclodextrin polymer (CDP)-based nanoparticles such as, for example, CDP-admantane (AD)-PEG conjugates and CDP-AD-PEG-transferrin conjugates.
- CDP Cyclodextrin polymer
- nanoparticles are formulated with Cas9 mRNA chemically modified to reduce TLR responses, as disclosed in Kormann et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29: 154-157 (2011).
- the nanoparticles are formulated using controlled microfluidic mixing systems, as disclosed in, for example, Chen et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Amer. Chem. Soc. 134:6948-6951 (2012).
- the lipid-based delivery system comprises a lipid encapsulation system.
- the lipid encapsulation system can be designed to drive the desired tissue distribution and cellular entry properties, as well as to provide the requisite circulation time and biodegrading character.
- the lipid encapsulation may involve reverse micelles and/or further comprise polymeric matrices.
- the particle includes a lipophilic delivery compound to enhance delivery of the particle to tissues, including in a preferential manner.
- Such compounds may generally include lipophilic groups and conjugated amino acids or peptides, including linear or cyclic peptides, and including isomers thereof.
- the lipid or polymeric particles may have a size (e.g., an average size) in the range of about 50 nm to about 5 ⁇ m. In some embodiments, the particles are in the range of about 10 nm to about 100 ⁇ m, or about 20 nm to about 50 ⁇ m, or about 50 nm to about 5 ⁇ m, or about 70 nm to about 500 nm, or about 70 nm to about 200 nm, or about 50 nm to about 100 nm. Particles may be selected so as to avoid rapid clearance by the immune system. Particles may be spherical, or non-spherical.
- the non-viral delivery vehicle may be a peptide, such as a cell-penetrating peptides or cellular internalization sequences.
- Cell penetrating peptides are small peptides that are capable of translocating across plasma membranes.
- Exemplary cell-penetrating peptides include, but are not limited to, Antennapedia sequences, TAT, HIV-Tat, Penetratin, Antp-3A (Antp mutant), Buforin II, Transportan, MAP (model amphipathic peptide), K-FGF, Ku70, Prion, pVEC, Pep-1, SynB I, Pep-7, I-IN-1, BGSC (Bis-Guanidinium-Spermidine-Cholesterol, and BGTC (B is-Guanidinium-Tren-Cholesterol).
- the guide RNA or RNA encoding the modified nucleic acid editing system is modified at the 5′ end or the 3′ end In a preferred embodiment, the modification is made at the 3′ end of the RNA.
- the RNA may be modified by conjugating to cholesterol, other lipophilic molecules, polymers, peptides, antibodies, aptamers, and/or small molecules.
- the RNA is conjugated to a N-acetylgalactosamine (GaINAc).
- GaINAc binds the asialoglycoprotein receptor (ASGPR) on hepatocytes, and therefore can be used to target an RNA to the liver.
- the RNA is conjugated to a trivalent targeting ligand, e.g., triantennary GaINAc.
- Such conjugates comprise an RNA conjugated at the 3′ terminus to three GaINAc molecules.
- the delivery vehicles may be administered by any method known in the art, including injection, optionally by direct injection to target tissues.
- the guide RNA, modified nucleic acid editing system, and, optionally, donor DNA are administered simultaneously in the same or in different delivery vehicles.
- the guide RNA and modified nucleic acid editing system and, optionally, donor DNA are administered sequentially via the same or separate delivery vehicles.
- the guide RNA and/or donor DNA is administered 1, 3, 5, 7, 10, 14, or 30 days prior to administration of the modified nucleic acid editing system, such that the guide RNA and/or donor DNA accumulates in the target cell or tissue prior to administration of the modified nucleic acid editing system.
- the guide RNA, donor DNA and/or nucleic acid editing system is administered in a plurality of doses, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more doses.
- the gRNA, donor DNA and/or nucleic acid editing system is administered over a time period of from one day week to about a month.
- one or both of the guide RNA and donor DNA are provided in an AAV vector that is administered to the tissue or cell prior to administration of the modified nucleic acid editing system.
- the AAV vector comprising the gRNA is administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days prior to the administration of the nanoparticle modified nucleic acid editing system, to allow expression of the guide RNA from the AAV vector.
- the modified nucleic acid editing system is administered multiple times, for example, once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days.
- the donor DNA is delivered via an AAV vector, and is injected 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days prior to the administration of either or both of the modified nucleic acid editing system and the guide RNA.
- either or both of guide RNA and donor DNA are provided in an AAV vector that is administered first, and the modified nucleic acid editing system is administered subsequently in a lipid-based delivery vehicle in one or more doses.
- each component of the compositions described herein are each delivery using a different vehicles, alternatively one or more components may be used with the same deliver vehicle.
- the modified nucleic acid editing system, guide RNA, and donor DNA are administered at multiple time points, for example, every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 days.
- the administration of the modified nucleic acid editing system, guide RNA and donor DNA are administered at different time points.
- expression of the modified nucleic acid editing system is transient. In some embodiments, such transient expression of the modified nucleic acid editing system minimizes off-target effects. For example, expression of the modified nucleic acid editing system is controlled via selection of the delivery vehicles and/or promoters.
- the present disclosure provides compositions and methods that allow for increased safety and/or efficacy of conventional nucleic acid editing systems.
- the methods disclosed herein provide for repeated dosing with conventional and modified nucleic acid editing systems such that the efficiency of gene editing increases with each dose.
- the methods disclosed herein result in an increase in efficiency of gene editing by conventional nucleic acid editing systems when used in conjunction with the modified nucleic acid editing systems disclosed herein.
- the percentage efficiency of gene editing increases by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about
- At least one of the guide RNA, modified nucleic acid editing system, and donor DNA are administered to a tissue or cell at the same time, such as on the same delivery vehicle, and one or more component (i.e., the modified nucleic acid editing system, and guide RNA) is under the control of an inducible promoter.
- the inducible promoter may be for example a small molecule-induced promoter such as tetracycline-inducible promoter.
- the delivery vehicles may be administered by any method known in the art, including injection, optionally by direct injection to target tissues or cells.
- Nucleic acid modification can be monitored over time by, for example, periodic biopsy with PCR amplification and/or sequencing of the target region from genomic DNA, or by RT-PCR and/or sequencing of the expressed transcripts. Alternatively, nucleic acid modification can be monitored by detection of a reporter gene or reporter sequence. Alternatively, nucleic acid modification can be monitored by expression or activity of a modified gene product or a therapeutic effect in the cell or tissue or in a subject.
- the cell or tissue is in a subject.
- the subject may be a human, in particular a human in need of therapeutic or prophylactic intervention.
- the subject is an animal, including livestock, poultry, domesticated animal, or laboratory animal.
- the subject is a mammal, such as a human, horse, cow, dog, cat, rodent, or pig.
- the methods provided herein include obtaining a cell or population of cells from a subject and modifying a target polynucleotide in the cell or cells ex vivo, using the delivery systems, compositions, methods, and/or kits disclosed herein.
- the ex vivo modified cell or cells may be re-introduced into the subject following ex vivo modification.
- the present disclosure provides methods for treating a disease or disorder in a subject, comprising obtaining one or more cells from the subject, modifying one or more target nucleotide sequences in the cell ex vivo using both conventional and the modified nucleic acid editing systems described herein and re-introducing of the cell with the modified target nucleotide sequence back into the subject having the disease or disorder.
- cells in which nucleotide sequence modification has occurred are expanded in vitro prior to reintroduction into the subject having the disease or disorder.
- At least one of the modified nucleic acid editing system, guide RNA and donor DNA are administered to a cell in vitro.
- At least one component e.g., the guide RNA, donor, modified nucleic acid editing system or nucleic acid vector
- a cell or tissue which may be, for example, liver, heart, lung (including airway epithelial cells), skeletal muscle, CNS (e.g., nerve cells), endothelial cells, blood cells, bone marrow cells, blood cell precursor cells, stem cells, fat cells, or immune cells.
- Tissue targeting or distribution can be controlled by selection and design a viral delivery vehicle, or in some embodiments is achieved by selection and design of lipid or polymeric delivery vehicles.
- the percentage efficiency of target sequence modification (editing) using the methods disclosed herein is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 99%.
- the efficiency of target sequence modification (editing) using the methods and compositions disclosed herein provides a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, a 7-fold increase or more compared to methods of making the same modification (edit) without tethering the donor DNA.
- the efficiency of target sequence modification is less than 100%, or wherein an effect on fewer than 100% of the cells has a therapeutic effect.
- a therapeutic effect may be achieved when the efficiency of nucleic acid modification of about 0.01% to about 100%, about 0.01% to about 50%, about 0.05% to about 40%, about 0.1% to about 30%, about 0.5% to about 25%, about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, or about 1% to about 5%.
- nucleotide sequence modification is relatively low (e.g., less than 50%, or less than 40%, or less than 30%, or less than 20%, or less than 10%, or less than 5%, or less than 1%, or less than 0.5%, or less than 0.1%), modest expression of the introduced or corrected or modified gene product may result in a therapeutic effect in the disease or disorder.
- the delivery systems and compositions disclosed herein are formulated such that the ratio of the components is optimized for consistent delivery to the target sequence.
- the ratio of the guide RNA and modified nucleic acid editing system is optimized for consistent delivery to the target sequence.
- the ratio of the donor DNA to the guide RNA and/or to the modified nucleic acid editing system is optimized for consistent delivery to the target sequence.
- the ratio of modified Cas9:guideRNA:donor is from about 1:1:1 to about 1:1:100.
- the ratio is from about 1:1:2 to about 1:1:90, from about 1:1:5 to about 1:1:75, or from about 1:1:10 to about 1:1:50.
- the ratio is about 1:1:1 or below, such as from about 1:1:0.01 to about 1:1:1, from about 1:1:0.02 to about 1:1:0.75, or about 1:1:0.05 to about 1:1:0.5, or about 1:1:0.1 to about 1:1:0.5.
- the ratio of modified nucleic acid editing system:donor DNA is from about 1:100 to about 100:1, or about 1:50 to about 50:1, or about 1:25 to about 25:1, or about 1:10 to about 10:1, or about 1:5 to about 5:1, or about 1:2 to about 2:1, or about 1:1.
- kits containing any one or more of the components disclosed in the above methods, compositions, and delivery systems may be provided individually or in combinations, and may be provided in any suitable container, such as a vial, a bottle, or a tube.
- the kits disclosed herein comprise one or more reagents for use in the embodiments disclosed herein.
- a kit may provide one or more reaction or storage buffers.
- Reagents may be provided in a form that is usable in a particular method, or in a form that requires addition of one or more other components before use (e.g. in concentrate or lyophilized form).
- Suitable buffers include, but are not limited to, phosphate buffered saline, sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof.
- the buffer is alkaline.
- the buffer has a pH from about 7 to about 10.
- a kit may comprise: a donor DNA and a modified nucleic acid editing system.
- the kit may further comprise a guide RNA.
- the kit may provide an expression system providing for expression of either or both of the modified nucleic acid editing system and guide RNA in a target cell.
- the kit may provide one or more doses of an RNA delivery system, each dose providing for expression of the modified nucleic acid editing system in the target cell or tissue.
- the kit may be custom made for use with user defined target sequences.
- Example 1 Plasmid for Tethering Crispr/Cas9 Complex to a Genomic Target DNA Sequence
- FIG. 2 is a map of a plasmid vector containing an active Cas 9 gene sequence and its guide RNA.
- the coding sequence of Cas9 is contiguous with a lac repressor DNA binding domain. This fusion is operably linked to a CMV promoter. When expressed lac repressor DNA binding domain binds the lac operator sequence in the plasmid backbone sequence.
- Donor DNA complementary to a genomic target DNA sequence is also cloned into the vector and provides a template for homologous recombination between the Crispr/Cas9 generated double-strand break in the target DNA sequence.
- the donor DNA sequence is modified to prevent binding of the Crispr/Cas9 nuclease to plasmid sequence and contains selectable markers to aid in identification of recombinant cell lines. It is contemplated that the donor DNA sequence may contain mutant DNA sequences to change the function of the target chromosomal gene or it may contain a ‘wild type’ sequence to correct a mutant target DNA sequence.
- FIGS. 3 and 4 are maps of plasmids used in a binary system where the Crispr/Cas9 gene sequence containing the lac repressor fusion and guide RNA are present on a tether expression vector ( FIG. 3 ) and the donor DNA sequence is present on a second tethered gene targeting vector ( FIG. 4 ). Co-transfection of both vectors is necessary for expression of the target-specific Crispr/Cas9/lac repressor nuclease binds the lac operator sequence on the tethered targeting plasmid ( FIG. 4 ) thus localizing the gene targeting plasmid to the target DNA.
- sequences of complementary oligonucleotides used to clone the lactose operator sequence or tetracycline resistance operator sequence into HindIII/SaII restriction endonuclease digested pUC19.
- the correct orientation allows subsequent cloning of LacO and TetO duplexes into pUC19 to generate plasmids with one or more sequential operators that can be used to clone donor DNA molecules for gene editing by homology directed recombination in mammalian cells.
- FIGS. 5 and 6 are plasmid maps of vectors for an in vitro tethering system whereby purified Crispr/Cas9 is used to bind a gene targeting vector prior to transfection into cells.
- the His-tagged Crispr/Cas9-lac repressor fusion is expressed from the plasmid shown in FIG. 5 , the fusion is then purified by immobilized metal affinity chromatography.
- FIG. 5 indicates that the Lac represser protein operator-binding domain is fused to the c-terminus of the CAS9 9.
- a preferable arrangement is that the lac repressor is fused to the N-terminus of Cas9 preferably using a linker such as the XTEN linker.
- the purified fusion protein is the mixed with a gene targeting vector (i.e. FIG. 4 ).
- the complex of purified fusion protein and gene targeting vector is transfected into cells with the guide RNA expression plasmid ( FIG. 6 ).
- Cystic fibrosis is one of the most prevalent genetic diseases found in the Caucasian population with as many as 1/27 individuals carrying a mutation in the CFTR gene.
- the most common mutation found in CF patients is the deIF508, or F508del, mutation that is the result of an in frame 3 base pair deletion in exon 11 resulting in a loss of phenylalanine at residue 508 in the protein.
- Several immortalized human cell lines have been generated from CF patients, including the CFBE41o-cell line homozygous for the deIF508 mutation.
- the CFTR gene sequence in HEK293 cells is a normal, or wild type, CFTR gene sequence.
- the px458 Cas9 vector was modified by engineering a lactose repressor protein, or tetracycline repressor protein, fused in frame with the Cas9 protein sequence to create a “GeneTether”.
- This GeneTether modification enables binding of donor DNA molecules used for gene editing to the functional Cas9 protein and localizes the donor DNA molecule at the Cas9-generated double strand break to enhance homology directed repair, reduce on-target mutations, and reduce induction of the P53 DNA repair system.
- These modified Cas9 proteins were transfected into cells with donor DNA molecules containing lactose operator or tetracycline operator DNA sequences to measure the gene editing efficiency introducing the deIF508 mutation into the normal HEK293 CFTR gene
- the lactose and tetracycline repressor proteins bind well-defined operator sequences with high specificity and affinity.
- GeneTethers are lactose or tetracycline repressor proteins fused with Cas9 (and other Cas proteins), TALENS, or ZNF with that will bind to DNA molecules containing the respective operator sequences. Binding of GeneTether-modified Cas proteins, TALENs, or ZNF to their genomic target will thereby physically localize any DNA molecules, bound to the repressor protein fusion, to the same genomic site ( FIG. 1 ). Localization of DNA molecules, homologous to the genomic DNA target sequences, enhance the efficiency of gene editing by the homologous directed recombination DNA repair pathways and minimize DNA mutations.
- the lactose repressor gene was amplified by polymerase chain reaction from Escherichia coli DH5a using lacI Primer 2f/Primer 2r (Table 2) and the Q5 high fidelity thermostable polymerase (New England Biolabs) according to vendor instructions.
- the 1083 base pair product was gel-purified (Monarch DNA Gel Extraction Kit, New England Biolabs) and used for further modifications.
- Two BbsI restriction endonuclease sites in the Lactose repressor gene sequence were inactivated using polymerase chain reaction amplification with the mutagenic primers lacIBbs2f, lacIBbs2r, lacIBbs3f, and laciBbs3r to generate A to G transitions in codons 164 and 277, retaining glutamic acid codons (Figure LacIBbsAssembled).
- FIG. 8 Construction of the lactose repressor-Cas9 fusion was performed as outlined in FIG. 8 .
- Three overlapping DNA fragments amplified by polymerase chain reaction with the Q5 high fidelity polymerase were cloned into AgeI/BgIII digested pSpCas9 BB-2A-GFP(px458) (Genescript, Inc) to generate the GeneTether lactose repressor-Cas9 fusion plasmid pGT1 ( FIG. 8D , SEQ ID NO 63) using the NEBuilder system (New England Biolabs).
- the three, polymerase chain reaction products used for this assembly were generated using the polymerase chain reaction primers to the px458 vector Primer1fAge/Primer1r, and Primer3f/Primer3r, and the BbsI-inactivated Lactose repressor gene was amplified using Primer2f/Primer2r (Table 2).
- the resulting plasmid, pGT1 was screened for by colony polymerase chain reaction and the Lactose repressor-Cas9 fusion gene sequence was confirmed by DNA sequencing (Quintara Biosciences), restriction endonuclease mapping, and diagnostic polymerase chain reaction amplification.
- the three, polymerase chain reaction products used for this assembly were generated using the polymerase chain reaction primers to the px458 vector Primer1fAge/Primer1r, and Primer3f/Primer3r, and the Tetracycline repressor gene was amplified using the primers NLS Linker primer1f/tet linker Cas9 Primer 1r.
- the resulting plasmid, pGT9 (SEQ ID NO: 63), was screened for by colony polymerase chain reaction and the Tetracycline repressor-Cas9 fusion gene sequence was confirmed by DNA sequencing (Quintara Biosciences), restriction endonuclease mapping, and diagnostic polymerase chain reaction amplification.
- Guide RNA Cloning Guide RNA sequences were designed to bind the exon 11 gene sequence of the wild type CFTR gene and the CFTR del-F508 mutant gene sequence (Table 3).
- the guide DNA oligonucleotides were annealed to create duplex molecules with Bbs1 compatible overhang and were subsequently ligated into gel-purified BbsI restriction endonuclease digested px458, pGT1, and pGT9.
- aCFTR Donor DNA Generation 5 kilobasepair CFTR DNA fragments approximately centered on the CFTR gene exon 11 were generated by polymerase chain reaction using the Q5 high fidelity DNA polymerase and primers CF96310f and CF101310r. Donor DNA fragments containing the CFTR deIF508 mutation were generated using genomic DNA from the CFBE410-cell line that is homozygous for the deIF508 mutation. Donor DNA fragments containing the wild type (nonmutant) CFTR gene sequence were generated using genomic DNA from the HEK293 cell line.
- Donor DNA fragments used for gene editing were modified at the 5′ or 3′ end of the fragment to contain either the lactose operator sequence (AATTGTGAGCGCTCACAATT, SEQ ID NO: 57) or tetracycline operator sequence (CACTCCCTATCAGTGATAGAGAAA SEQ ID NO: 58).
- lactose operator sequence AATTGTGAGCGCTCACAATT, SEQ ID NO: 57
- CACTCCCTATCAGTGATAGAGAAA SEQ ID NO: 58 tetracycline operator sequence
- polymerase chain reaction amplification using the Q5 high fidelity thermostable DNA polymerase with the primer pairs lacOsymCF1f/CF5r to add the lactose operator sequence to the 5′ end of the donor DNA or primer pairs Cf1f/lacOsymCF5r to add the lactose operator to the 3′ end of the donor DNA fragment (Figure Donor DNA Molecules).
- Donor DNA molecules with the tetracycline operator sequence were generated using the primer pairs tetoCF1f/CF5r and CF1f/tetoCF5r. Donor DNA fragments were gel-purified prior to use in cell transfections for gene editing.
- HEK293 cells were transfected in 12-well plates using Lipofectamine 3000 (Invitrogen, Inc) with 500 ng of plasmid DNA and 500 ng of gel purified donor DNA fragments.
- the px458, pGT1, and pGT9 plasmids contain a green fluorescent protein reporter gene that is expressed in transfected cells and allows monitoring of transfection efficiencies. Green fluorescent protein expression was visualized by fluorescence microscopy at approximately 48 hours post transfection. At 48-72 hours post transfection, 12-well plates of transfected cells were washed once with phosphate buffered saline and stored at ⁇ 80° C. until DNA was harvested for analysis of gene editing efficiencies.
- the presence of the deIF508 mutation in a population of CFTR wild type cells can be detected using polymerase chain reaction with Taq polymerase and the primer pair CF1 Bf/CF8Cr. Since the CF1 Bf primer is located 5′ or outside of the donor DNA fragment, the 388 basepair product is generated from an “inside-out” approach and is specifically diagnostic for gene edited events and will not amplify randomly integrated or unintegrated donor DNA molecules.
- Genomic DNA was prepared directly from each well of a 12-well plate (Genejet Genomic Purification Kit, ThermoFisher, Inc) and DNA concentration determined by ultraviolet spectroscopy. Allele specific polymerase chain reactions were performed on 100 ng of genomic DNA and 500 ⁇ M primer, 1.5 mM MgCl 2 , HotStart Taq polymerase (New England Biolabs).
- the thermocycler program for semiquantitative amplification of the deIF508 mutant DNA sequence was 95° C., 2 minutes; 35 cycles of 95° C., 30 seconds, 50° C., 30 seconds, 72° C., 1 minute; followed by 72° C., 8 minutes.
- the 388 base pair polymerase chain reaction product was visualized with ultraviolet light on a 1.5% agarose gel stained with Gelred (Biotium, Inc).
- a 1.5% agarose gel stained with Gelred Biotium, Inc.
- standard genomic DNA samples with varying ratios of wild type and deIF508 mutant DNA were amplified in parallel to experimental DNA samples.
- Two different tethers (lactose-repressor-Cas9 fusion or tetracycline repressor-Cas9 fusion) were used in combination with donor DNA molecules containing a 5′ lactose or tetracycline operator sequence or a 3′ lactose or tetracycline operator sequence ( FIGS. 11 and 12 ) and containing the deIF508 deletion sequence.
- Homology directed repair by homologous recombination between the genomic CFTR target Cas9-induced double strand break and donor fragment would catalyze transfer of the deIF508 DNA sequence to the genomic target ( FIG. 12 ).
- Cas9 guides complementary to the nonmutated wild type CFTR exon 11 DNA sequence, but not to the deIF508 DNA sequence were selected to allow recognition of the genomic DNA target and prevent the Cas9 enzyme from recognizing, and cleaving, the deIf508 donor DNA fragment.
- HEK293 cells Approximately 5 ⁇ 10 5 HEK293 cells per well were seeded, 24 hours before transfection, into Corning 12-well tissue culture plates such that the wells were 50-80% confluent at the time of transfection. The media on the cells was changed prior to transfection.
- px458, pGT1 or pGT9 was mixed with 500 ng of donor DNA fragment in 50 ⁇ L of DMEM medium. 2 ⁇ L of the P3000 reagent was then added to the DNA/DMEM solution, mixed well, and allowed to incubate at room temperature for 5 minutes.
- a solution of Lipofectamine 3000 was made by adding 1.5 ⁇ L of undiluted Lipofectamine 3000 to 50 ⁇ L of DMEM and equal volumes of DNA/DMEM solutions and Lipofectamine/DMEM solutions were mixed and incubated at room temperature for 12-15 minutes. 100 ⁇ L of the DNA/P3000/Lipofectamine solution was then added per well of Corning 12-well plates. Two days after transfection the cells are examined with fluorescent microscopy to assess the extent of successful transfection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The technology relates to a composition for tethering donor DNA to a nuclease, the composition comprising a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of: a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence; and a nucleic acid encoding the fusion protein.
Description
- This application claims priority to Australian provisional patent application No 2018900990 filed 25 Mar. 2018 which is herein incorporated by reference in its entirety.
- The technology relates to compositions for tethering donor DNA to a nuclease the use of those compositions for improving the efficiency of in vivo gene editing.
- A number of genome editing technologies are known including Transcription Activator-Like Effector Nucleases (TALENs), the CRISPR-Cas9 system (Clustered, Regularly Interspaced, Short Palindromic Repeats and CRISPR associated protein 9), and Zinc finger nucleases (ZFNs). TALENs, CRISPR-Cas9 protein and ZFNs use endonucleases to initiate double-strand breaks (DSBs) at almost any target sequence in genomic DNA and can be used for gene knockouts, gene knock-ins, gene tagging, and correction of genetic defects.
- The type II bacterial clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system is a tool for the targeted introduction of mutations into cellular DNA. Well-designed single guide (sg) RNAs induce Cas9-mediated double stranded breaks (DSBs) at desired target sites in cellular DNA while minimizing effects at other locations. Double stranded breaks stimulate DNA repair by at least two distinct mechanisms non-homologous end joining (NHEJ) and homology directed repair (HDR). Cas9-mediated modification of cellular DNA by NHEJ can reach efficiencies of 20-60% but because NHEJ is error-prone and introduces unpredictable patterns of insertions and deletions it is only suitable for introducing small random mutations. Co-application CRISPR-Cas9 with a single-stranded or double-stranded DNA template homologous to the sequences flanking the cleavage site on the cellular DNA enables precise genome editing by HDR-mediated incorporation of an exogenous, or donor DNA fragment. However, the frequency of HDR is inherently low and the efficiency of insertion of a donor DNA using this strategy is only 0.5-20%.
- TALENs are fusions of transcription activator-like (TAL) proteins and a Fok I nuclease. TAL proteins are typically composed of 33-34 amino acid repeating motifs with two variable positions that have a strong recognition for specific nucleotide sequences. By assembling arrays of TALs and fusing them to a Fok I nuclease, specific cutting of the genome can be achieved. When two TALENs bind and meet, the Fok I domains induce a double-strand break which can inactivate a gene, or can be used to insert DNA of interest. TALENs are able to modify chromosomes with efficiency of up to about 33%.
- ZFNs are a class of engineered DNA-binding proteins that allow targeted genome editing of the genome by creating double-strand breaks in DNA at desired locations. ZFNs consist of two functional domains, a DNA-binding domain comprised of a chain of Zinc-finger modules, each recognizing a unique DNA hexamer. Multiple Zinc-fingers can be assembled to form ZFN with specificity for a sequence of 24 bases or more. The second functional domain is the nuclease domain of Fok I. Using ZFNs can result in single or biallelic edits occurring at an efficiency of 1-20% of clone population.
- The present inventor has developed compositions and methods that utilise the target specificity of gene editing systems such as CRISPR-Cas9, TALENs and ZFNs to tether a donor DNA to a desired target DNA sequence.
- In a first aspect, there is provided a composition comprising a composition for tethering donor DNA to a nuclease, the composition comprising a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of:
- a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence; and
- a nucleic acid encoding the fusion protein.
- The nuclease may be a Cas, a Transcription activator-like effector nuclease (TALEN), a meganuclease, or a Zinc Finger. In one embodiment the is a Cas protein, for example Cas9
- The fusion protein may further comprises a nuclear localization sequence.
- The composition may further comprise a guide RNA that interacts with the Cas protein and a target DNA sequence.
- The consensus sequence may comprise the Lac operator (SEQ ID NO: 66), the TRP operator (SEQ ID NO: 68), the TET operator (SEQ ID NO: 67), the GAL-4 binding site (SEQ ID NO: 1), or the IHF binding site (SEQ ID NO 2).
- The consensus sequence may comprise a sequence with at least 80%, 85%, 90%, 95% or at least 99% identity to the Lac operator, the TRP operator, the TET operator, the GAL-4 binding site, or the IHF binding site
- The DNA biding domain may comprises the LAC repressor, TET repressor, TRP-repressor, GAL-4, or IHF, or a portion thereof sufficient to bind the consensus sequence.
- The DNA binding domain is the LAC repressor, preferably amino acids 43-403 of SEQ ID NO 9.
- The nuclease may be coupled to the DNA binding domain via a linker. The linker may comprise a sequence selected from any one of SEQ ID Nos: 3 to 7, a GGS linker, or amino acids 404-419 of SEQ ID NO 9.
- In one embodiment the fusion protein comprises the LAC repressor and Cas9.
- The composition may comprise a vector, wherein the vector comprises either or both of:
- a. the nucleic acid comprising the donor DNA and the consensus sequence for a DNA binding domain; and
- b. the nucleic acid encoding the fusion protein.
- The vector may further comprise a nucleic acid sequence encoding a guide RNA that interacts with the Cas9 and a target DNA sequence.
- In some embodiments the fusion protein is nuclease deficient.
- In a second aspect there is provided an isolated host cell comprising the composition of the first aspect.
- In a third aspect there is provided a method for editing DNA in a cell, the method comprising;
- contacting the cell with the composition of the first aspect under conditions suitable for the interaction of the fusion protein with a target DNA sequence.
- In a third aspect there is provided a method for editing DNA in a cell, the method comprising
- a) contacting the cell with the composition of
claim 15 under conditions suitable for the interaction of the fusion protein with a first target DNA sequence; and - b) contacting the cell with a nucleic acid editing system adapted to edit the genomic DNA at a second target DNA sequence, under conditions suitable for nucleic acid editing.
- The target DNA sequence may be selected from genomic DNA, mitochondrial DNA, viral DNA, or exogenous DNA.
- In one embodiment the efficiency of editing is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 99%.
- The cell may be in a subject, preferably a human subject.
- In a fourth aspect there is provided a kit comprising:
- a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of
-
- a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence; and
- a nucleic acid encoding the fusion protein.
- In one embodiment the fusion protein in the kit comprises a Cas protein, a Transcription activator-like effector nuclease (TALEN), a meganuclease, a Zinc Finger or a MADzyme. In one embodiment the Cas is Cas9.
- Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
- Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this specification.
- In order that the present invention may be more clearly understood, preferred embodiments will be described with reference to the following drawings and examples.
-
FIG. 1 is a depiction of two embodiments of the composition disclosed herein comprising a modified nucleic acid editing system. -
FIG. 2 is a map of a plasmid vector containing an active Cas 9 gene sequence and its guide RNA capable of directing binding of the Crispr/Cas9 complex to a genomic target DNA sequence, donor DNA sequence that can be used for repair of Crispr/Cas9 induced double strand breaks. -
FIG. 3 is a map of a plasmid used in a binary system where the Crispr/Cas9 gene sequence containing the lac repressor fusion and guide RNA are present on a tether expression vector and the donor DNA sequence is present on a second tethered gene targeting vector. -
FIG. 4 is a map of a plasmid used in a binary system where the Crispr/Cas9 gene sequence containing the lac repressor fusion and guide RNA are present on a tether expression vector and the donor DNA sequence is present on a second tethered gene targeting vector. -
FIG. 5 is a map of a plasmid for generating an in vitro system whereby purified Crispr/Cas9 would is used to bind a gene targeting vector prior to transfection into cells. -
FIG. 6 is a map of a plasmid for generating an in vitro system whereby purified Crispr/Cas9 would is used to bind a gene targeting vector prior to transfection into cells. -
FIG. 7 is a workflow diagram for construction of an in vivo tethered gene-targeting plasmid, where A represents the synthesis of U6 expression cassette containing Ug promoter with a central SspI recognition sequence and flanking SspI compatible overhangs that do not reconstruct the plasmid SspI recognition sequence. B represents the synthesis of CMV promoter-SV40-polyA cassette containing central NotI cloning site and Eco109I compatible overhangs. C represents Synthesis of gene encoding Cas9-lac repressor fusion protein with NotI compatible overhangs. D represents synthesis of gene encoding RNA complementary to genomic target DNA sequence with SspI compatible overhangs. E represent PCR amplification of donor DNA sequence with oligonucleotide containing flanking SaII restriction endonuclease recognition sequences and digestions with SaII. -
FIG. 8A is a workflow diagram for the construction of pGT1. Construction of lactose repressor gene with inactivated BbsI restriction endonuclease sites. -
FIG. 8B is a workflow diagram for the construction of pGT1. -
FIG. 8C is a workflow diagram for the construction of pGT1. Three overlapping DNA fragments comprising Flag/SV40 NLS, lacI and Cas9 were made, and these were cloned into pSpCas9 BB-2A-GFP(px458). -
FIG. 8D is a vector map if pGT1. -
FIG. 9 is a vector map of the ptet repressor plasmid used in the construction of pGT9. -
FIG. 10A is a workflow diagram for the construction of pGT9. A tet repressor cassette was cloned into pUC57 to create ptet repressor. -
FIG. 10B is a workflow diagram for the construction of pGT9. Three polymerase chain reaction products, Flag/SV40 NLS, lacI and Cas9, were generated. -
FIG. 10C is a workflow diagram for the construction of pGT9. Three polymerase chain reaction products, Flag/SV40 NLS, lacI and Cas9 were cloned into pSpCas9 BB-2A-GFP(px458). -
FIG. 10D is a vector map of pGT9. -
FIG. 11 is an overview of a donor fragment, showing a 500 pase pair donor fragment with deIF508 Mutation and lacO or tetO Recognition Sequences -
FIG. 12 is an overview of the use of the compositions described herein for homology directed repair by homologous recombination between the genomic CFTR target Cas9-induced double strand break and donor fragment to catalyze transfer of the deIF508 DNA sequence to the genomic target. -
FIG. 13 illustrates that combination of pGT1 vector (lactose repressor-Cas9 fusion) with the 130117 guide (genomic target forward strand) and lactose operator on the 3′ end of donor DNA (FIG. 13 , lane 7) demonstrates higher gene editing efficiency as compared to the px458 vector with unmodified Cas9 and same donor DNA fragment -
FIG. 14 illustrates that gene editing with the pGT9 tetracycline repressor-Cas9 fusion vector, guide sequences, and donor fragments did not yield appreciably better gene editing frequencies than the control px458 vector - The present disclosure provides compositions, methods, and kits for tethering donor DNA to a DNA target sequence with a modified nucleic acid editing system. The disclosure provides for improved efficiency of in vivo cellular DNA modification (such as gene editing) using a modified nucleic acid editing system, such as CRISPR-Cas9. One embodiment of this process is illustrated in
FIG. 1 . The modified gene editing system is adapted a bind to a nucleic acid comprising donor DNA and tether the nucleic acid to a specific site on the cellular DNA at or near to the nucleotide sequence to be edited. - The compositions and methods described herein can include a nuclease of any nucleic acid editing system capable of site specific binding. For example, useful nucleases include Cas nucleases, TALENs, meganucleases, ZFNs and MADzymes. The nuclease is modified by combining it with a DNA binding domain.
- The nuclease and the DNA binding domain may be joined via linker. Suitable linkers include for example, linkers comprising the sequences (Gly-Gly-Gly-Gly-Ser)n, (Gly)n, or (Gly)nS, (EAAAK)n, (AP)n, (XP)n, or A(EAAAK)n where n is any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 and X is any amino acid. Other suitable linkers comprise the sequences KESGSVSSEQLAQFRSLD, EGKSSGSGSESKST, GSAGSAAGSGEF, KESGSVSSEQLAQFRSLE, or GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG.
- Cas systems are divided into three major types (type I, type II, and type III) and twelve subtypes, which are based on their genetic content and structural differences. However, the core defining features of all CRISPR-Cas systems are the Cas genes and their proteins: cas1 and cas2 are universal across types and subtypes, while Cas3, Cas9, and Cas10 are signature genes for type I, type II, and type III, respectively.
- Any Cas may be used. For example the Cas nuclease may be Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10. In some embodiments the Cas is Cas9.
- Cas9 (CRISPR associated protein 9) is an RNA-guided DNA nuclease used to induce site-directed double strand breaks in DNA for the gene inactivation or the introduction of heterologous genes through non-homologous end joining and homologous recombination respectively. Systems and nucleic acids sequences for expressing Cas9 are commercially available. The Cas9 may be codon optimized for a human or other mammalian system. The Cas9 protein may contain a nuclear localization signal at the C-terminus. The RNA encoding Cas9 may be capped and polyadenylated to support expression in mammalian cells, and may contain modifications to reduce immune stimulation. The amino acid sequence and encoding nucleic acid sequence for Cas9 and functional derivatives and homologs which can be used in the compositions and methods are known in the art.
- The Cas9 may be delivered in conjunction with a guide RNA (gRNA) that directs the editing system to the nucleotide sequence recognized by the gRNA. In general, a gRNA can be designed to target any nucleotide sequence. The gRNA structure is disclosed in, for example, Ran F A, Genome editing using the CRISPR-Cas9 System. PNAS 8(1 1):2281-308 (2013); and Pyzocha et al., RNA-guided genome editing of mammalian cells. Methods Mol. Biol. 1 1 14:269-77 (2014), which are hereby incorporated by reference in their entirety. Generally for Cas9, gRNAs guide the Cas9 to the complementary 20 nucleotide sequences with a downstream NGG protospacer-adjacent motif (PAM).
- The CRISPR-Cas9 system including the construction of guide sequences is further disclosed in U.S. Pat. No. 8,697,359, which is hereby incorporated by reference in its entirety.
- In place of a CRISPR-Cas9 system, alternate nucleic acid editing systems may be used. For example, suitable systems include any CRISPR/cas system (e.g., any Cascade-like CRISPR/cas, Type I CRISPR cas, Type II CRISPR/cas, and type III CRISPR/cas), zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, homing endonucleases, and MADzymes (for examples the Human or E. coli MADzymes encoded by SEQ ID Nos: 69 and 70, respectively.
- The DNA binding domain component of the modified nucleic acid editing system can be any sequence specific high affinity DNA binding domain. The term ‘DNA binding domain’ as used herein refers to any complete protein or fragment thereof which can bind DNA. Accordingly the term ‘DNA binding domain’ includes complete proteins such as the LAC repressor and fragments of the protein which retain the DNA binding
- In some embodiments the DNA binding domain is not mammalian in order to reduce of target effects. For example the DNA binding domain may be from a bacteria or yeast. DNA binding domains useful in the compositions and methods described herein can be selected from the group consisting of be the LAC repressor, TET repressor, TRP-repressor, GAL-4, or IHF. Each of these bind specific consensus sequences that are known in the art.
- The consensus sequence may be the Lac operator (e.g. SEQ ID NO: 66), the TRP operator (e.g. SEQ ID NO: 68), the TET operator (e.g. SEQ ID NO: 67), the GAL-4 binding site (5′-CGG-N11-CCG-3′) or the IHF binding site (5′-WATCAANNNNTTR-3′). W is A or T, and R is A or G, and N is any nucleotide.
- The nucleic acid editing systems can be present in the compositions disclosed herein in the form of purified proteins or in the form of nucleic acids encoding the nucleic acid editing system. The nucleic acid may be a vector, for example a plasmid vector comprising sequences encoding the nucleic acid editing system operably linked to a constitutive or inducible promoter.
- The term “vector” includes a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes. Certain exemplary vectors may be plasmids, lentiviruses or adeno-associated viruses. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are expression vectors capable of directing the expression of genes to which they are operatively linked. Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. Recombinant expression vectors can comprise one or more nucleic acids encoding a modified nucleic acid editing system in a form suitable for expression of the nucleic acid in a cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression. That is the regulatory elements are operatively-linked to the nucleic acid sequence to be expressed. ‘Operably linked’ means that that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- ‘Regulatory element’ includes promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory elements are known in the art. Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes).
- Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector may comprise one or more poI Ill promoter (e.g. 1, 2, 3, 4, 5, or more poI III promoters), one or more poI H promoters (e.g. 1, 2, 3, 4, 5, or more poI H promoters), one or more poI I promoters (e.g. 1, 2, 3, 4, 5, or more poI 1 promoters), or combinations thereof. Examples of poI III promoters include, but are not limited to, U6 and HI promoters. Examples of poI II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol Kinase (PGK) promoter, and the EFIa promoter and Poi H promoters described herein. Also encompassed by the term “regulatory element” are enhancer elements, such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-1; SV40 enhancer; and the intron sequence between
exons - The vector may include one or more terminator sequences. A terminator sequence includes a section of nucleic acid sequence that marks the end of a coding sequence during transcription.
- The vector may include one or more sequences encoding an epitope tag or reporter gene sequences, Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemaglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HAP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and auto-fluorescent proteins including blue fluorescent protein (BFP). The epitope tag, reporter gene or both may be expressed from the vector as a fusion with the modified nucleic acid editing system (nuclease-DNA binding domain fusion).
- Alternatively or in addition the compositions may comprise a mRNA encoding the fusion protein.
- The mRNA can be modified, and the modification selected from one or more of modifications of the phosphate backbone (e.g., phosphorothioate linkages or boranophosphate linkages), ribose ring modifications such as 2′-0-methyl and/or 2′-fluoro and/or 4′-thio modifications, and locked or unlocked nucleic acids. Other modifications may include pseudouridine, 2-thiouridine, 4-thiouridine, 5-azauridine, 5-hydroxyuridine, 5-aminouridine, 5-methyluridine, 2-thiopseudouridine, 4-thiopseudouridine, 5-hydroxypseudouridine, 5-methylpseudouridine, 5-aminopseudouridine, pseudoisocytidine, 5-methylcytidine, N4-methylcytidine, 2-thiocytidine, 5-azacytidine, 5-hydroxycytidine, 5-aminocytidine, N4-methylpseudoisocytidine, 2-thiopseudoisocytidine, 5-hydroxypseudoisocytidine, 5-aminopseudoisocytidine, 5-methylpseudoisocytidine, N6-methyladenosine, 7-deazaadenosine, 6-thioguanosine, 7-deazaguanosine, 8-azaguanosine, 6-thio-7-deazaguanosine, 6-thio-8-azaguanosine, 7-deaza-8-azaguanosine, and 6-thio-7-deaza-8-azaguanosine.
- In some embodiments the modifications are selected for one or more of the following: reduce immune stimulation, RNA stabilization, improve expression of the encoded protein. For example, the RNA may have a combination of 2-thiouridine and 5-methyl-cytidine to reduce immune stimulation through pattern recognition receptors such as TLR3, TLR7 and TLR8. In some embodiments, the mRNA has one or more pseudouridine to stabilize the mRNA against cleavage, and improve expression rates.
- The modified nucleic acid editing systems also comprise a DNA binding domain. The DNA binding domain facilitates the localisation of the modified nucleic acid editing system to cellular DNA.
- Construction of the vectors disclosed herein is by standard methods known in the art such as ligation of synthetic nucleic acids, or nucleic acids produced by, for example PCR, into a plasmid that has been cut by one or more site-specific nucleases.
- There are alternative strategies for producing the vectors disclosed herein. In one approach, the entire vector(s) are synthesized de novo using a commercially available service, for example by a company that specialises in the synthesis of large DNA molecules.
- Alternatively, a combination of classical cloning techniques and synthetic biology to modify a standard laboratory plasmid such as pUC19. In this approach, gene cassettes encoding the Cas9-lac operon fusion gene, guide RNA, and donor DNA sequences would be synthesized de novo and individually cloned into unique restriction endonuclease sites present in the vector backbone using T4 DNA ligase. Donor DNA sequences are amplified by polymerase chain reaction to generate products that are cloned into the vector backbone. Modification of Cas9-lac repressor fusion proteins to add other DNA binding domains or epitopes for affinity purification of modified Cas9 proteins can be performed by recombinant PCR followed by ligation into restriction endonuclease sites in the vector backbone. A workflow illustrating this process for preparing the plasmid vectors disclosed herein is shown in
FIG. 7 . - in some embodiments the nucleic acid editing system is nuclease deficient. In these embodiments the nuclease deficient nucleic acid editing system is used to tether the donor DNA near to a target nucleic acid sequence so that donor DNA is available for use by an additional nucleic acid editing system.
- For example the nuclease deficient gene editing system has reduced or eliminated nuclease activity, alternatively the nuclease activity is absent or substantially absent within levels of detection. In some embodiments the nuclease activity of the gene editing system may be undetectable using known assays, i.e. below the level of detection of known assays.
- Nuclease deficient gene editing systems can be prepared by those skilled in the art using standard molecular biology techniques. Typically this involves deleting or altering one or more amino acids crucial for nuclease activity to substantially eliminate or eliminate nuclease activity.
- In some embodiments the Cas9 is a nuclease-deficient Cas9. A nuclease-deficient Cas9 may be one in which one or more amino acids in Cas9 are altered or removed. For example a nuclease deficient Cas9 may be generated by removing or mutating one or more of the amino acids D10, H840, D839 and N863 (See Jinke et al., Science 337, 816-821 (2012). For example one or more of these amino acids may be deleted or substituted with alanine or glycine to substantially eliminates or eliminates nuclease activity.
- The term “donor DNA” includes a nucleic acid sequence which is to be inserted into cellular DNA (such as of genomic DNA, mitochondrial DNA, or viral DNA). The donor nucleic acid sequence may be expressed by the cell. The donor nucleic can be exogenous, foreign to the cell or non-naturally occurring within the cell.
- The donor DNA is associated with a sequence that can be bound by a DNA binding domain. For example the donor DNA may be contiguous with a consensus sequence for a DNA binding domain or may be present on the same vector as the a consensus sequence, or may be present on the same polynucleotide as the consensus sequence.
- A target nucleic acid sequence includes any nucleic acid sequence, such as a genomic nucleic acid sequence or a gene to which a nuclease of a nucleic acid editing system can co-localise. Target nucleic acids include nucleic acid sequences capable of being expressed into proteins. According to one aspect, the target nucleic acid is genomic DNA, mitochondrial DNA, plastid DNA, viral DNA, or exogenous DNA.
- One of skill in the art will readily be able to identify or design guide RNAs, TALENs, ZFNs, meganucleases and homing endonucleases which co-localize to a target nucleic acid sequence.
- The compositions and vectors described herein can be used in for editing DNA in a cell. The methods comprise contacting the cell with a composition comprising a modified gene editing system or vector encoding a modified gene editing system under conditions suitable for the interaction of the modified nucleic acid editing system with a target DNA sequence. The methods also comprise use of a nuclease-deficient modified nucleic acid editing system that interacts with a first target DNA sequence and a conventional nucleic acid editing system to edit the DNA at a second target DNA sequence.
- In order to increase the efficiency of DNA editing the donor DNA is positioned close to the target DNA sequence so that it is readily available for nucleic acid editing.
- In embodiments using a nuclease-deficient modified nucleic acid editing system this is achieved by spacing the first and second target sequences so that the donor DNA is closed to the conventional nucleic acid editing system when it is colocalised with its target sequence.
- For example the first and second target sequences are about 75 to 150 base pairs apart, about 150-250, 250-350, 450-550, 550-650, 650-750, 750-850, 850-950, 950-1050 base pairs apart or about 1-1.5 kb apart.
- The methods require delivery of the compositions or vectors to the cell. Methods of non-viral delivery of nucleic acid vectors, RNA or proteins include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, agent-enhanced uptake of DNA, nanoparticles, and electroporation/nucleofection. Lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides are known. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration). The term native includes the protein, enzyme, RNA, or guide RNA species itself as well as the corresponding nucleic acid encoding the same.
- Delivery vehicles for the compositions and vectors disclosed herein provided herein may be viral vectors or non-viral vectors. In some embodiments, the modified nucleic acid editing system is provided in a viral vector or a non-viral vector. In other embodiments, the guide RNA is provided in a viral vector, and the modified nucleic acid editing system is provided in a non-viral vector. In still other embodiments, the guide RNA is provided in a non-viral vector and the modified nucleic acid editing system is provided in a viral vector
- In some embodiments, the viral vector is selected from an adeno-associated virus (AAV), adenovirus, retrovirus, and lentivirus vector. While the viral vector may deliver any component of the system described herein so long as it provides the desired profile for tissue presence or expression, in some embodiments the viral vector provides for expression of one or more of the modified nucleic acid editing system, guide RNA and optionally the delivers the donor DNA. In some embodiments, the viral delivery system is adeno-associated virus (AAV) 2/8. However, in various embodiments other AAV serotypes are used, such as AAV1, AAV2, AAV4, AAV5, AAV6, and AAV8. In some embodiments, AAV6 is used when targeting airway epithelial cells, AAV7 is used when targeting skeletal muscle cells (similarly for AAV1 and AAV5), and AAV8 is used for hepatocytes. In some embodiments, AAV1 and 5 can be used for delivery to vascular endothelial cells. Further, most AAV serotypes show neuronal tropism, while AAV5 also transduces astrocytes. In some embodiments, hybrid AAV vectors are employed. In some embodiments, each serotype is administered only once to avoid immunogenicity. Thus, subsequent administrations employ different AAV serotypes.
- In some embodiments, the delivery system comprises a non-viral delivery vehicle. In some aspects, the non-viral delivery vehicle is lipid-based. In other aspects, the non-viral delivery vehicle is a polymer. In some embodiments, the non-viral delivery vehicle is biodegradable. In embodiments, the non-viral delivery vehicle is a lipid encapsulation system and/or polymeric particle.
- In certain embodiments, the delivery system comprises lipid particles. In some embodiments, the lipid-based vector is a lipid nanoparticle, which is a lipid particle between about 1 and about 100 nanometers in size. In some embodiments, the lipid-based vector is a lipid or liposome. Liposomes are artificial spherical vesicles comprising a lipid bilayer.
- The lipid-based vector can be a small nucleic acid-lipid particle (SNALP). SNALPs comprise small (less than 200 nm in diameter) lipid-based nanoparticles that encapsulate a nucleic acid. In some embodiments, the SNALP is useful for delivery of an RNA molecule. In some embodiments, SNALP formulations deliver nucleic acids to a particular tissue in a subject, such as the liver.
- In some embodiments, the guide RNA, the modified nucleic acid editing system (or the RNA encoding the same) is delivered via polymeric vectors. In some embodiments, the polymeric vector is a polymer or polymerosome. Polymers encompass any long repeating chain of monomers and include, for example, linear polymers, branched polymers, dendrimers, and polysaccharides. Linear polymers comprise a single line of monomers, whereas branched polymers include side chains of monomers. Dendrimers are also branched molecules, which are arranged symmetrically around the core of the molecule. Polysaccharides are polymeric carbohydrate molecules, and are made up of long monosaccharide units linked together. Polymersomes are artificial vesicles made up of synthetic amphiphilic copolymers that form a vesicle membrane, and may have a hollow or aqueous core within the vesicle membrane.
- Various polymer-based systems can be used for administering RNA encoding modified nucleic acid editing system. Exemplary polymeric materials include poly(D,L-lactic acid-co-glycolic acid) (PLGA), poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), PLGA-b-poly(ethylene glycol)-PLGA (PLGA-bPEG-PLGA), PLLA-bPEG-PLLA, PLGA-PEG-maleimide (PLGA-PEG-mal), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacralate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) (polyacrylic acids), and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate), polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, polyvinylpyrrolidone, polyortho esters, polyphosphazenes, Poly([beta]-amino esters (PBAE), and polyphosphoesters, and blends and/or block copolymers of two or more such polymers. Polymer-based systems may also include Cyclodextrin polymer (CDP)-based nanoparticles such as, for example, CDP-admantane (AD)-PEG conjugates and CDP-AD-PEG-transferrin conjugates.
- In one embodiment, nanoparticles are formulated with Cas9 mRNA chemically modified to reduce TLR responses, as disclosed in Kormann et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29: 154-157 (2011). In a further embodiment, the nanoparticles are formulated using controlled microfluidic mixing systems, as disclosed in, for example, Chen et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Amer. Chem. Soc. 134:6948-6951 (2012).
- In some embodiments, the lipid-based delivery system comprises a lipid encapsulation system. The lipid encapsulation system can be designed to drive the desired tissue distribution and cellular entry properties, as well as to provide the requisite circulation time and biodegrading character. The lipid encapsulation may involve reverse micelles and/or further comprise polymeric matrices. In some embodiments, the particle includes a lipophilic delivery compound to enhance delivery of the particle to tissues, including in a preferential manner. Such compounds may generally include lipophilic groups and conjugated amino acids or peptides, including linear or cyclic peptides, and including isomers thereof.
- The lipid or polymeric particles may have a size (e.g., an average size) in the range of about 50 nm to about 5 μm. In some embodiments, the particles are in the range of about 10 nm to about 100 μm, or about 20 nm to about 50 μm, or about 50 nm to about 5 μm, or about 70 nm to about 500 nm, or about 70 nm to about 200 nm, or about 50 nm to about 100 nm. Particles may be selected so as to avoid rapid clearance by the immune system. Particles may be spherical, or non-spherical.
- In some embodiments, the non-viral delivery vehicle may be a peptide, such as a cell-penetrating peptides or cellular internalization sequences. Cell penetrating peptides are small peptides that are capable of translocating across plasma membranes. Exemplary cell-penetrating peptides include, but are not limited to, Antennapedia sequences, TAT, HIV-Tat, Penetratin, Antp-3A (Antp mutant), Buforin II, Transportan, MAP (model amphipathic peptide), K-FGF, Ku70, Prion, pVEC, Pep-1, SynB I, Pep-7, I-IN-1, BGSC (Bis-Guanidinium-Spermidine-Cholesterol, and BGTC (B is-Guanidinium-Tren-Cholesterol).
- In some embodiments, the guide RNA or RNA encoding the modified nucleic acid editing system is modified at the 5′ end or the 3′ end In a preferred embodiment, the modification is made at the 3′ end of the RNA. The RNA may be modified by conjugating to cholesterol, other lipophilic molecules, polymers, peptides, antibodies, aptamers, and/or small molecules. In some embodiments, the RNA is conjugated to a N-acetylgalactosamine (GaINAc). GaINAc binds the asialoglycoprotein receptor (ASGPR) on hepatocytes, and therefore can be used to target an RNA to the liver. In some embodiments, the RNA is conjugated to a trivalent targeting ligand, e.g., triantennary GaINAc. Such conjugates comprise an RNA conjugated at the 3′ terminus to three GaINAc molecules.
- The delivery vehicles (e.g. conjugates, viral or non-viral vectors, or any combination thereof) may be administered by any method known in the art, including injection, optionally by direct injection to target tissues. In some embodiments, the guide RNA, modified nucleic acid editing system, and, optionally, donor DNA are administered simultaneously in the same or in different delivery vehicles. In other embodiments, the guide RNA and modified nucleic acid editing system and, optionally, donor DNA are administered sequentially via the same or separate delivery vehicles. In some embodiments, the guide RNA and/or donor DNA is administered 1, 3, 5, 7, 10, 14, or 30 days prior to administration of the modified nucleic acid editing system, such that the guide RNA and/or donor DNA accumulates in the target cell or tissue prior to administration of the modified nucleic acid editing system. In some embodiments, the guide RNA, donor DNA and/or nucleic acid editing system is administered in a plurality of doses, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more doses. In various embodiments, the gRNA, donor DNA and/or nucleic acid editing system is administered over a time period of from one day week to about a month.
- In one embodiment, one or both of the guide RNA and donor DNA, are provided in an AAV vector that is administered to the tissue or cell prior to administration of the modified nucleic acid editing system. In a further embodiment, the AAV vector comprising the gRNA is administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days prior to the administration of the nanoparticle modified nucleic acid editing system, to allow expression of the guide RNA from the AAV vector. In a yet further embodiment, the modified nucleic acid editing system is administered multiple times, for example, once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days.
- In another embodiment, the donor DNA is delivered via an AAV vector, and is injected 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days prior to the administration of either or both of the modified nucleic acid editing system and the guide RNA.
- In particular embodiments, either or both of guide RNA and donor DNA are provided in an AAV vector that is administered first, and the modified nucleic acid editing system is administered subsequently in a lipid-based delivery vehicle in one or more doses.
- In another embodiment, each component of the compositions described herein (e.g., the modified nucleic acid editing system, guide RNA and donor DNA) are each delivery using a different vehicles, alternatively one or more components may be used with the same deliver vehicle. In a further embodiment, the modified nucleic acid editing system, guide RNA, and donor DNA, are administered at multiple time points, for example, every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 days. In another embodiment, the administration of the modified nucleic acid editing system, guide RNA and donor DNA are administered at different time points.
- In some embodiments, expression of the modified nucleic acid editing system is transient. In some embodiments, such transient expression of the modified nucleic acid editing system minimizes off-target effects. For example, expression of the modified nucleic acid editing system is controlled via selection of the delivery vehicles and/or promoters.
- In some embodiments, the present disclosure provides compositions and methods that allow for increased safety and/or efficacy of conventional nucleic acid editing systems. Advantageously, the methods disclosed herein provide for repeated dosing with conventional and modified nucleic acid editing systems such that the efficiency of gene editing increases with each dose. For example, in some embodiments, the methods disclosed herein result in an increase in efficiency of gene editing by conventional nucleic acid editing systems when used in conjunction with the modified nucleic acid editing systems disclosed herein. For example the percentage efficiency of gene editing increases by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, or more.
- In another embodiment at least one of the guide RNA, modified nucleic acid editing system, and donor DNA are administered to a tissue or cell at the same time, such as on the same delivery vehicle, and one or more component (i.e., the modified nucleic acid editing system, and guide RNA) is under the control of an inducible promoter. As an example, in one embodiment the inducible promoter may be for example a small molecule-induced promoter such as tetracycline-inducible promoter.
- The delivery vehicles (whether viral vector or non-viral vector or RNA conjugate material) may be administered by any method known in the art, including injection, optionally by direct injection to target tissues or cells. Nucleic acid modification can be monitored over time by, for example, periodic biopsy with PCR amplification and/or sequencing of the target region from genomic DNA, or by RT-PCR and/or sequencing of the expressed transcripts. Alternatively, nucleic acid modification can be monitored by detection of a reporter gene or reporter sequence. Alternatively, nucleic acid modification can be monitored by expression or activity of a modified gene product or a therapeutic effect in the cell or tissue or in a subject.
- In some embodiments, the cell or tissue is in a subject. For example the subject may be a human, in particular a human in need of therapeutic or prophylactic intervention. Alternatively, the subject is an animal, including livestock, poultry, domesticated animal, or laboratory animal. In various embodiments, the subject is a mammal, such as a human, horse, cow, dog, cat, rodent, or pig.
- In some embodiments, the methods provided herein include obtaining a cell or population of cells from a subject and modifying a target polynucleotide in the cell or cells ex vivo, using the delivery systems, compositions, methods, and/or kits disclosed herein. In further embodiments, the ex vivo modified cell or cells may be re-introduced into the subject following ex vivo modification. Thus, the present disclosure provides methods for treating a disease or disorder in a subject, comprising obtaining one or more cells from the subject, modifying one or more target nucleotide sequences in the cell ex vivo using both conventional and the modified nucleic acid editing systems described herein and re-introducing of the cell with the modified target nucleotide sequence back into the subject having the disease or disorder. In some embodiments, cells in which nucleotide sequence modification has occurred are expanded in vitro prior to reintroduction into the subject having the disease or disorder.
- In other embodiments, at least one of the modified nucleic acid editing system, guide RNA and donor DNA are administered to a cell in vitro.
- In some embodiments, at least one component (e.g., the guide RNA, donor, modified nucleic acid editing system or nucleic acid vector) accumulates in a cell or tissue which may be, for example, liver, heart, lung (including airway epithelial cells), skeletal muscle, CNS (e.g., nerve cells), endothelial cells, blood cells, bone marrow cells, blood cell precursor cells, stem cells, fat cells, or immune cells. Tissue targeting or distribution can be controlled by selection and design a viral delivery vehicle, or in some embodiments is achieved by selection and design of lipid or polymeric delivery vehicles.
- In some embodiments, the percentage efficiency of target sequence modification (editing) using the methods disclosed herein is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 99%.
- In some embodiments, the efficiency of target sequence modification (editing) using the methods and compositions disclosed herein provides a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, a 7-fold increase or more compared to methods of making the same modification (edit) without tethering the donor DNA.
- In some embodiments, the efficiency of target sequence modification is less than 100%, or wherein an effect on fewer than 100% of the cells has a therapeutic effect. For example, a therapeutic effect may be achieved when the efficiency of nucleic acid modification of about 0.01% to about 100%, about 0.01% to about 50%, about 0.05% to about 40%, about 0.1% to about 30%, about 0.5% to about 25%, about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, or about 1% to about 5%. Thus, even if the efficiency of nucleotide sequence modification is relatively low (e.g., less than 50%, or less than 40%, or less than 30%, or less than 20%, or less than 10%, or less than 5%, or less than 1%, or less than 0.5%, or less than 0.1%), modest expression of the introduced or corrected or modified gene product may result in a therapeutic effect in the disease or disorder.
- In some embodiments, the delivery systems and compositions disclosed herein are formulated such that the ratio of the components is optimized for consistent delivery to the target sequence. In one embodiment, the ratio of the guide RNA and modified nucleic acid editing system is optimized for consistent delivery to the target sequence. In another embodiment, the ratio of the donor DNA to the guide RNA and/or to the modified nucleic acid editing system is optimized for consistent delivery to the target sequence. For example, in one embodiment, the ratio of modified Cas9:guideRNA:donor is from about 1:1:1 to about 1:1:100. In a further embodiment, the ratio is from about 1:1:2 to about 1:1:90, from about 1:1:5 to about 1:1:75, or from about 1:1:10 to about 1:1:50. In other embodiments, the ratio is about 1:1:1 or below, such as from about 1:1:0.01 to about 1:1:1, from about 1:1:0.02 to about 1:1:0.75, or about 1:1:0.05 to about 1:1:0.5, or about 1:1:0.1 to about 1:1:0.5. In other embodiments, wherein the composition does not include a guide RNA, the ratio of modified nucleic acid editing system:donor DNA is from about 1:100 to about 100:1, or about 1:50 to about 50:1, or about 1:25 to about 25:1, or about 1:10 to about 10:1, or about 1:5 to about 5:1, or about 1:2 to about 2:1, or about 1:1.
- In one aspect, there is provides kits containing any one or more of the components disclosed in the above methods, compositions, and delivery systems. Kit components may be provided individually or in combinations, and may be provided in any suitable container, such as a vial, a bottle, or a tube. In some embodiments, the kits disclosed herein comprise one or more reagents for use in the embodiments disclosed herein. For example, a kit may provide one or more reaction or storage buffers. Reagents may be provided in a form that is usable in a particular method, or in a form that requires addition of one or more other components before use (e.g. in concentrate or lyophilized form). Suitable buffers include, but are not limited to, phosphate buffered saline, sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH from about 7 to about 10.
- For example, a kit may comprise: a donor DNA and a modified nucleic acid editing system. The kit may further comprise a guide RNA. The kit may provide an expression system providing for expression of either or both of the modified nucleic acid editing system and guide RNA in a target cell. The kit may provide one or more doses of an RNA delivery system, each dose providing for expression of the modified nucleic acid editing system in the target cell or tissue.
- The kit may be custom made for use with user defined target sequences.
- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
-
FIG. 2 is a map of a plasmid vector containing an active Cas 9 gene sequence and its guide RNA. The coding sequence of Cas9 is contiguous with a lac repressor DNA binding domain. This fusion is operably linked to a CMV promoter. When expressed lac repressor DNA binding domain binds the lac operator sequence in the plasmid backbone sequence. - Donor DNA complementary to a genomic target DNA sequence is also cloned into the vector and provides a template for homologous recombination between the Crispr/Cas9 generated double-strand break in the target DNA sequence. In one embodiment the donor DNA sequence is modified to prevent binding of the Crispr/Cas9 nuclease to plasmid sequence and contains selectable markers to aid in identification of recombinant cell lines. It is contemplated that the donor DNA sequence may contain mutant DNA sequences to change the function of the target chromosomal gene or it may contain a ‘wild type’ sequence to correct a mutant target DNA sequence.
-
FIGS. 3 and 4 are maps of plasmids used in a binary system where the Crispr/Cas9 gene sequence containing the lac repressor fusion and guide RNA are present on a tether expression vector (FIG. 3 ) and the donor DNA sequence is present on a second tethered gene targeting vector (FIG. 4 ). Co-transfection of both vectors is necessary for expression of the target-specific Crispr/Cas9/lac repressor nuclease binds the lac operator sequence on the tethered targeting plasmid (FIG. 4 ) thus localizing the gene targeting plasmid to the target DNA. - The sequences of complementary oligonucleotides used to clone the lactose operator sequence or tetracycline resistance operator sequence into HindIII/SaII restriction endonuclease digested pUC19. The correct orientation allows subsequent cloning of LacO and TetO duplexes into pUC19 to generate plasmids with one or more sequential operators that can be used to clone donor DNA molecules for gene editing by homology directed recombination in mammalian cells.
-
TABLE 1 LacO and TetO Oligonucleotides. SEQ Name Sequence ID NO tetO w TCGAGTTTACCACTCCCTATCAGTGATAGAG 59 AAAAGTGAAAG tetO c TCGACTTTCACTTTTCTCTATCACTGATAGG 60 GAGTGGTAAAC lacO w TCGAGTTTAGTGGAATTGTGAGCGGATAACA 61 ATTTCACTGAAAG lacO c TCGACTTTCAGTGAAATTGTTATCCGCTCAC 62 AATTCCACTAAAC -
FIGS. 5 and 6 are plasmid maps of vectors for an in vitro tethering system whereby purified Crispr/Cas9 is used to bind a gene targeting vector prior to transfection into cells. The His-tagged Crispr/Cas9-lac repressor fusion is expressed from the plasmid shown inFIG. 5 , the fusion is then purified by immobilized metal affinity chromatography.FIG. 5 indicates that the Lac represser protein operator-binding domain is fused to the c-terminus of the CAS9 9. However, as set out in SEQ ID NOS: 8 and 9 a preferable arrangement is that the lac repressor is fused to the N-terminus of Cas9 preferably using a linker such as the XTEN linker. In any case the purified fusion protein is the mixed with a gene targeting vector (i.e.FIG. 4 ). The complex of purified fusion protein and gene targeting vector is transfected into cells with the guide RNA expression plasmid (FIG. 6 ). - Cystic fibrosis is one of the most prevalent genetic diseases found in the Caucasian population with as many as 1/27 individuals carrying a mutation in the CFTR gene. The most common mutation found in CF patients is the deIF508, or F508del, mutation that is the result of an in
frame 3 base pair deletion inexon 11 resulting in a loss of phenylalanine at residue 508 in the protein. Several immortalized human cell lines have been generated from CF patients, including the CFBE41o-cell line homozygous for the deIF508 mutation. The CFTR gene sequence in HEK293 cells, however, is a normal, or wild type, CFTR gene sequence. - In this example, the px458 Cas9 vector was modified by engineering a lactose repressor protein, or tetracycline repressor protein, fused in frame with the Cas9 protein sequence to create a “GeneTether”. This GeneTether modification enables binding of donor DNA molecules used for gene editing to the functional Cas9 protein and localizes the donor DNA molecule at the Cas9-generated double strand break to enhance homology directed repair, reduce on-target mutations, and reduce induction of the P53 DNA repair system. These modified Cas9 proteins were transfected into cells with donor DNA molecules containing lactose operator or tetracycline operator DNA sequences to measure the gene editing efficiency introducing the deIF508 mutation into the normal HEK293 CFTR gene
- The lactose and tetracycline repressor proteins bind well-defined operator sequences with high specificity and affinity. GeneTethers are lactose or tetracycline repressor proteins fused with Cas9 (and other Cas proteins), TALENS, or ZNF with that will bind to DNA molecules containing the respective operator sequences. Binding of GeneTether-modified Cas proteins, TALENs, or ZNF to their genomic target will thereby physically localize any DNA molecules, bound to the repressor protein fusion, to the same genomic site (
FIG. 1 ). Localization of DNA molecules, homologous to the genomic DNA target sequences, enhance the efficiency of gene editing by the homologous directed recombination DNA repair pathways and minimize DNA mutations. - The lactose repressor gene was amplified by polymerase chain reaction from Escherichia coli DH5a using lacI Primer 2f/
Primer 2r (Table 2) and the Q5 high fidelity thermostable polymerase (New England Biolabs) according to vendor instructions. The 1083 base pair product was gel-purified (Monarch DNA Gel Extraction Kit, New England Biolabs) and used for further modifications. Two BbsI restriction endonuclease sites in the Lactose repressor gene sequence were inactivated using polymerase chain reaction amplification with the mutagenic primers lacIBbs2f, lacIBbs2r, lacIBbs3f, and laciBbs3r to generate A to G transitions in codons 164 and 277, retaining glutamic acid codons (Figure LacIBbsAssembled). Three gel-purified, Q5 high fidelity polymerase, polymerase chain reaction products using primer pairslacI primer 1f/lacI Bbs Primer 2r, lacI Bbs Primer 2f/lacI Bbs Primer 3r, andlacI Bbs Primer 3f/lacI Primer 1 r (Table 2) were used to reconstruct thefull length 1083 base pair BbsI-inactivated Lactose repressor protein gene (NEBuilder HiFi Assembly, New England Biolabs). -
TABLE 2 PCR Primer DNA Sequences. SEQ ID Primer Sequence NO CF1Bf CCTTCTCTGTGAACCTCTATCA 10 CF1f GCAGAGTACCTGAAACAGGA 11 CF5r CATTCACAGTAGCTTACCCA 12 CF7Cr ATAGGAAACACCAAAGATGA 13 CF8Cr ATAGGAAACACCAATGATAT 14 CF8Crfull ATAGGAAACACCAATGATATTTTCTTTAAT 15 GGTGCCAGGC CF9Cf GAAAATATCATTGGTGTTTCCTATGATGAA 16 TATAGATACAG CF96250f TGAGTTAGATGTTTGACGC 17 CF96310f GCTGTGCATTTTCCTCTGGGTAATACTTTA 18 G CF98236f GTCTCTATTACTTAATCTGTACCT 19 CF98328f CTGTGAAGATTAAATAAATTAATATAGTTA 20 AAGCAC CF99287r ATGCTCATTCCATTAGGCTATAGTATTA 21 CF99310r CTAATTCTCTGCTGGCAGATCAATGC 22 CF101310r CAAGACGTTGTGTTAGGTACATTACATGTA 23 CATC lacI Bbs CTCCCATGAGGACGGTACGCGACTGGGC 24 Primer 2f lacI Bbs GCCCAGTCGCGTACCGTCCTCATGGGAG 25 Primer 2rlacI Bbs GTGGGATACGACGATACCGAGGACAGCTCA 26 Primer 3fTGTTATATC lacI Bbs GATATAACATGAGCTGTCCTCGGTATCGTC 27 Primer 3r GTATCCCAC lacI Primer ATGAAACCAGTAACGTTATACGATGTCGC 28 1f lacI Primer TCACTGCCCGCTTTCCAG 29 1r lacI Primer GGTATCCACGGAGTCCCAGCAGCCATGAAA 30 2f CCAGTAACGTTAT Primer1fAge CTGGAGCACCTGCCTGAAATCAC 31 Primer1fXba CGCGTGCGCCAATTCTGCAGACAAATG 32 Primer1r TGCTGGGACTCCGTGGATACCGACCTTCCG 33 CTTC Primer2f GGTATCCACGGAGTCCCAGCAGCCGTGAAA 34 CCAGTAACGTTAT Primer2r GGCGGACTCTGAGGTCCCGGGAGTCTCGCT 35 GCCGCTCTGCCCGCTTTCCAG Primer3f CGGGACCTCAGAGTCCGCCACACCCGAAAG 36 TGACAAGAAGTACAGCATC Primer3r CGTCCACCTTGGCCATCTCGTTGCTG 37 lacOsymCF1f GTTCGGAATATAAATTGTGAGCGCTCACAA 38 TTAAGCTTGCAGAGTACCTGAAACAGGA lacOsymCF5r GTTCGGAATATAAATTGTGAGCGCTCACAA 39 TTAAGCTTCATTCACAGTAGCTTACCCA lacOsymCF5kf GTTCGGAATATAAATTGTGAGCGCTCACAA 40 TTAAGCTTGCTGTGCATTTTCCTCTGGGT lacOsymCF5kr GTTCGGAATATAAATTGTGAGCGCTCACAA 41 TTAAGCTTCAAGACGTTGTGTTAGGTACAT TACATGTAC pUC19polyCF5kr GAATTCGAGCTCGGTACCCGGGGATCCCAA 42 GACGTTGTGTTAGGTACATTACATGTAC pUC19polyCF5r GAATTCGAGCTCGGTACCCGGGGATCCCAT 43 TCACAGTAGCTTACCCA tetoCF5kf CACTCCCTATCAGTGATAGAGAAAAGAAAG 44 CTGTGCATTTTCCTCTGGGT tetoCF5kr CACTCCCTATCAGTGATAGAGAAACAAGAC 45 GTTGTGTTAGGTACATTACATGTACATC tetoCF1f CACTCCCTATCAGTGATAGAGAAAAGGCAG 46 AGTACCTGAAACAGGA tetoCF5r CACTCCCTATCAGTGATAGAGAAAAGCATT 47 CACAGTAGCTTACCCA 10635f CGGAGCCTATGGAAAAACGCCAGC 48 - Construction of the lactose repressor-Cas9 fusion was performed as outlined in
FIG. 8 . Three overlapping DNA fragments amplified by polymerase chain reaction with the Q5 high fidelity polymerase were cloned into AgeI/BgIII digested pSpCas9 BB-2A-GFP(px458) (Genescript, Inc) to generate the GeneTether lactose repressor-Cas9 fusion plasmid pGT1 (FIG. 8D , SEQ ID NO 63) using the NEBuilder system (New England Biolabs). The three, polymerase chain reaction products used for this assembly were generated using the polymerase chain reaction primers to the px458 vector Primer1fAge/Primer1r, and Primer3f/Primer3r, and the BbsI-inactivated Lactose repressor gene was amplified using Primer2f/Primer2r (Table 2). The resulting plasmid, pGT1, was screened for by colony polymerase chain reaction and the Lactose repressor-Cas9 fusion gene sequence was confirmed by DNA sequencing (Quintara Biosciences), restriction endonuclease mapping, and diagnostic polymerase chain reaction amplification. - The gene encoding the class B TN10 tetracycline repressor, with human codon preference, was ordered as a synthetic DNA molecule (Genescript, Inc) cloned into the pUC57 vector (
FIG. 9 and SEQ ID NO: 65). Construction of the tetracycline-repressor-Cas9 fusion was performed similar to the pGT1 lactose repressor-Cas9 fusion (FIG. 10 ). The three, polymerase chain reaction products used for this assembly were generated using the polymerase chain reaction primers to the px458 vector Primer1fAge/Primer1r, and Primer3f/Primer3r, and the Tetracycline repressor gene was amplified using the primers NLS Linker primer1f/tet linker Cas9 Primer 1r. The resulting plasmid, pGT9 (SEQ ID NO: 63), was screened for by colony polymerase chain reaction and the Tetracycline repressor-Cas9 fusion gene sequence was confirmed by DNA sequencing (Quintara Biosciences), restriction endonuclease mapping, and diagnostic polymerase chain reaction amplification. - Guide RNA Cloning Guide RNA sequences were designed to bind the
exon 11 gene sequence of the wild type CFTR gene and the CFTR del-F508 mutant gene sequence (Table 3). The guide DNA oligonucleotides were annealed to create duplex molecules with Bbs1 compatible overhang and were subsequently ligated into gel-purified BbsI restriction endonuclease digested px458, pGT1, and pGT9. -
TABLE 3 Guide Sequences. Shown are the DNA oligonucleotides for cloning into the BbsI sites in pGT1, pGT9, and pX458 Cas9 vectors SEQ Name Sequence ID NO CFWT 130117 fw CACCGATTAAAGAAAATATCATCTT 49 CFWT 130117 fc AAACAAGATGATATTTTCTTTAATC 50 CFWT 130121 rw CACCGAAAGATGATATTTTCTTTAA 51 CFWT 130121 rc AAACTTAAAGAAAATATCATCTTTC 52 delF 130127 fw CACCGACCATTAAAGAAAATATCAT 53 delF 130127 fc AAACATGATATTTTCTTTAATGGTC 54 delF 130138 rw CACCGACCAATGATATTTTCTTTAA 55 delF 130138 rc AAACTTAAAGAAAATATCATTGGTC 56 - aCFTR
Donor DNA Generation 5 kilobasepair CFTR DNA fragments approximately centered on theCFTR gene exon 11 were generated by polymerase chain reaction using the Q5 high fidelity DNA polymerase and primers CF96310f and CF101310r. Donor DNA fragments containing the CFTR deIF508 mutation were generated using genomic DNA from the CFBE410-cell line that is homozygous for the deIF508 mutation. Donor DNA fragments containing the wild type (nonmutant) CFTR gene sequence were generated using genomic DNA from the HEK293 cell line. - Donor DNA fragments used for gene editing were modified at the 5′ or 3′ end of the fragment to contain either the lactose operator sequence (AATTGTGAGCGCTCACAATT, SEQ ID NO: 57) or tetracycline operator sequence (CACTCCCTATCAGTGATAGAGAAA SEQ ID NO: 58). To generate 500 base pair donor DNA molecules, polymerase chain reaction amplification using the Q5 high fidelity thermostable DNA polymerase with the primer pairs lacOsymCF1f/CF5r to add the lactose operator sequence to the 5′ end of the donor DNA or primer pairs Cf1f/lacOsymCF5r to add the lactose operator to the 3′ end of the donor DNA fragment (Figure Donor DNA Molecules). Donor DNA molecules with the tetracycline operator sequence were generated using the primer pairs tetoCF1f/CF5r and CF1f/tetoCF5r. Donor DNA fragments were gel-purified prior to use in cell transfections for gene editing.
- Cell Transfection with Px458, pGT1, pGT9 Cas9 Vectors and 500 Base Pair Donor DNA Fragments
- HEK293 cells were transfected in 12-well plates using Lipofectamine 3000 (Invitrogen, Inc) with 500 ng of plasmid DNA and 500 ng of gel purified donor DNA fragments. The px458, pGT1, and pGT9 plasmids contain a green fluorescent protein reporter gene that is expressed in transfected cells and allows monitoring of transfection efficiencies. Green fluorescent protein expression was visualized by fluorescence microscopy at approximately 48 hours post transfection. At 48-72 hours post transfection, 12-well plates of transfected cells were washed once with phosphate buffered saline and stored at −80° C. until DNA was harvested for analysis of gene editing efficiencies.
- Analysis for the deIF508 Mutation by Allele-Specific Polymerase Chain Reaction Analysis
- The presence of the deIF508 mutation in a population of CFTR wild type cells can be detected using polymerase chain reaction with Taq polymerase and the primer pair CF1 Bf/CF8Cr. Since the CF1 Bf primer is located 5′ or outside of the donor DNA fragment, the 388 basepair product is generated from an “inside-out” approach and is specifically diagnostic for gene edited events and will not amplify randomly integrated or unintegrated donor DNA molecules.
- Genomic DNA was prepared directly from each well of a 12-well plate (Genejet Genomic Purification Kit, ThermoFisher, Inc) and DNA concentration determined by ultraviolet spectroscopy. Allele specific polymerase chain reactions were performed on 100 ng of genomic DNA and 500 μM primer, 1.5 mM MgCl2, HotStart Taq polymerase (New England Biolabs). The thermocycler program for semiquantitative amplification of the deIF508 mutant DNA sequence was 95° C., 2 minutes; 35 cycles of 95° C., 30 seconds, 50° C., 30 seconds, 72° C., 1 minute; followed by 72° C., 8 minutes. The 388 base pair polymerase chain reaction product was visualized with ultraviolet light on a 1.5% agarose gel stained with Gelred (Biotium, Inc). For semi-quantification of the PCR product, standard genomic DNA samples with varying ratios of wild type and deIF508 mutant DNA were amplified in parallel to experimental DNA samples.
- Two different tethers (lactose-repressor-Cas9 fusion or tetracycline repressor-Cas9 fusion) were used in combination with donor DNA molecules containing a 5′ lactose or tetracycline operator sequence or a 3′ lactose or tetracycline operator sequence (
FIGS. 11 and 12 ) and containing the deIF508 deletion sequence. Homology directed repair by homologous recombination between the genomic CFTR target Cas9-induced double strand break and donor fragment would catalyze transfer of the deIF508 DNA sequence to the genomic target (FIG. 12 ). - Cas9 guides complementary to the nonmutated wild
type CFTR exon 11 DNA sequence, but not to the deIF508 DNA sequence were selected to allow recognition of the genomic DNA target and prevent the Cas9 enzyme from recognizing, and cleaving, the deIf508 donor DNA fragment. - Approximately 5×105 HEK293 cells per well were seeded, 24 hours before transfection, into Corning 12-well tissue culture plates such that the wells were 50-80% confluent at the time of transfection. The media on the cells was changed prior to transfection.
- For transfections, 500 ng of px458, pGT1 or pGT9 was mixed with 500 ng of donor DNA fragment in 50 μL of DMEM medium. 2 μL of the P3000 reagent was then added to the DNA/DMEM solution, mixed well, and allowed to incubate at room temperature for 5 minutes. A solution of Lipofectamine 3000 was made by adding 1.5 μL of undiluted Lipofectamine 3000 to 50 μL of DMEM and equal volumes of DNA/DMEM solutions and Lipofectamine/DMEM solutions were mixed and incubated at room temperature for 12-15 minutes. 100 μL of the DNA/P3000/Lipofectamine solution was then added per well of Corning 12-well plates. Two days after transfection the cells are examined with fluorescent microscopy to assess the extent of successful transfection.
- Several variables for the effect of GeneTether modified Cas9 vectors on gene editing efficiency were tested: a lactose repressor-Cas9 fusion protein, tetracycline repressor-Cas9 fusion protein, Cas9 guides complementary to the top or bottom strand of genomic target, and 500 bp donor DNA molecules containing the deIF508 deletion with the lactose operator sequence at the 5′ or 3′ end of the donor DNA fragment.
- The combination of pGT1 vector (lactose repressor-Cas9 fusion) with the 130117 guide (genomic target forward strand) and lactose operator on the 3′ end of donor DNA (
FIG. 13 , lane 7) demonstrates higher gene editing efficiency as compared to the px458 vector with unmodified Cas9 and same donor DNA fragment (compare 388basepair products lane 3 and lane 7,FIG. 13 . Measurement of band intensities using ImageJ software (https://imagej.nih.gov) indicates that the tethered donor DNA complex has an approximate 7-fold higher gene editing efficiency compared to the px458 unmodified Cas9. Indeed, comparison of lane 7 band intensity to the reconstructed mixture of WT:deIF508 DNA (lanes 14-19) suggests the deIF508 mutation is present in approximately 10% of the genomic DNA. Since transfection efficiencies for these experiments were 10%, or less, up to 100% of cells transfected with the combination of pGT1/130117guide/3′ lactose operator sequence underwent successful gene editing. - Other combinations of pGT1/guide/donor DNA performed equal to or, slightly better than, unmodified Cas9 (
FIG. 13 ; lane 9 vs lane 5) for gene editing, demonstrating that the Cas9 protein activity was not affected by the lactose repressor fusion. The placement of the lactose operator sequence may slightly favor the 3′ placement (FIG. 13 ; lanes 7 and 9vs lanes 3 and 5). Donor DNA transfected with px458 not containing guide sequence showed low levels of gene editing (FIG. 13 ; lanes 10 and 11). Some faint 388 bp product is evident inlanes 10, 12, and 13 that is likely due to artifactual low-level mispriming of PCR primers used for the allele-specific PCR. - Gene editing with the pGT9 tetracycline repressor-Cas9 fusion vector, guide sequences, and donor fragments did not yield appreciably better gene editing frequencies than the control px458 vector (
FIG. 14 , lanes 2-5 vs lanes 6-9). The placement of the tetracycline at the 3′ end of the donor DNA fragment appears to result in slightly better gene editing efficiencies (FIG. 14 lanes 2, 4, 6, 8 vslanes - These results demonstrate that the GeneTether lactose repressor-Cas9 fusion protein encoded by pGT1 can significantly increases gene editing efficiency as compared to the unmodified Cas9 found in the px458 vector. Indeed, it is possible that the combination of pGT1/130117 guide/
deIF508 lacO 500 successfully caused gene editing of WT to deIF508 in almost 100% of transfected cells.
Claims (25)
1. A composition for tethering donor DNA to a nuclease, the composition comprising a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of:
a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence; and
a nucleic acid encoding the fusion protein.
2. The composition of claim 1 wherein the wherein the nuclease is a Cas protein, a Transcription activator-like effector nuclease (TALEN), a meganuclease, a Zinc Finger or a MADzyme.
3. The composition of claim 1 wherein the nuclease is a Cas protein.
4. The composition of claim 3 wherein the Cas protein is Cas9
5. The composition of claim 1 wherein the fusion protein further comprises a nuclear localization sequence.
6. The composition of claim 2 , further comprising a guide RNA that interacts with the Cas protein and a target DNA sequence.
7. The composition of claim 1 wherein the consensus sequence comprises the Lac operator (SEQ ID NO: 66), the TRP operator (SEQ ID NO: 68), the TET operator (SEQ ID NO 67), the GAL-4 binding site (SEQ ID NO: 1), or the IHF binding site (SEQ ID NO 2).
8. The composition of claim 7 wherein the consensus sequence comprises a sequence with at least 80%, 85%, 90%, 95% or at least 99% identity to the Lac operator, the TRP operator, the TET operator, the GAL-4 binding site, or the IHF binding site
9. The composition of claim 1 wherein the DNA biding domain comprises the LAC repressor, TET repressor, TRP-repressor, GAL-4, or IHF, or a portion thereof sufficient to bind the consensus sequence.
10. The composition of claim 1 wherein the DNA binding domain is the LAC repressor, preferably amino acids 43-403 of SEQ ID NO 9.
11. The composition of claim 1 wherein the nuclease is coupled to the DNA binding domain via a linker.
12. The composition of claim 11 wherein the linker comprises a sequence selected from any one of SEQ ID Nos: 3 to 7, a GGS linker, or amino acids 404-419 of SEQ ID NO 9.
13. The composition of claim 1 wherein the fusion protein comprises the LAC repressor and Cas9.
14. The composition of claim 1 comprising a vector, wherein the vector comprises either or both of:
a. the nucleic acid comprising the donor DNA and the consensus sequence for a DNA binding domain; and
b. the nucleic acid encoding the fusion protein.
15. The composition of claim 14 wherein the vector further comprises a nucleic acid sequence encoding a guide RNA that interacts with the Cas protein and a target DNA sequence.
16. The composition of claim 1 wherein the fusion protein is nuclease deficient.
17. An isolated host cell comprising the composition of claim 1 .
18. A method for editing DNA in a cell, the method comprising;
contacting the cell with the composition of claim 1 under conditions suitable for the interaction of the fusion protein with a target DNA sequence.
19. A method for editing DNA in a cell, the method comprising
a) contacting the cell with the composition of claim 16 under conditions suitable for the interaction of the fusion protein with a first target DNA sequence; and
b) contacting the cell with a nucleic acid editing system adapted to edit the genomic DNA at a second target DNA sequence, under conditions suitable for nucleic acid editing.
20. The method of claim 18 wherein the target DNA sequence is selected from genomic DNA, mitochondrial DNA, viral DNA, or exogenous DNA.
21. The method of claim 18 wherein the efficiency of editing is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 99%.
22. The method of claim 18 wherein the cell is in a subject, preferably a human subject.
23. A kit comprising:
a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of
a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence; and
a nucleic acid encoding the fusion protein.
24. The kit of claim 23 wherein the nuclease is a Cas protein, a Transcription activator-like effector nuclease (TALEN), a meganuclease, a Zinc Finger or a MADzyme.
25. The kit of claim 24 wherein the Cas protein is Cas9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/531,450 US20220325264A1 (en) | 2018-03-25 | 2021-11-19 | Modified nucleic acid editing systems for tethering donor dna |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018900990 | 2018-03-25 | ||
AU2018900990A AU2018900990A0 (en) | 2018-03-25 | Modified nucleic acid editing systems for tethering donor dna | |
US16/363,642 US11339385B2 (en) | 2018-03-25 | 2019-03-25 | Modified nucleic acid editing systems for tethering donor DNA |
US17/531,450 US20220325264A1 (en) | 2018-03-25 | 2021-11-19 | Modified nucleic acid editing systems for tethering donor dna |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/363,642 Continuation US11339385B2 (en) | 2018-03-25 | 2019-03-25 | Modified nucleic acid editing systems for tethering donor DNA |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220325264A1 true US20220325264A1 (en) | 2022-10-13 |
Family
ID=68062564
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/363,642 Active 2040-07-14 US11339385B2 (en) | 2018-03-25 | 2019-03-25 | Modified nucleic acid editing systems for tethering donor DNA |
US17/531,450 Pending US20220325264A1 (en) | 2018-03-25 | 2021-11-19 | Modified nucleic acid editing systems for tethering donor dna |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/363,642 Active 2040-07-14 US11339385B2 (en) | 2018-03-25 | 2019-03-25 | Modified nucleic acid editing systems for tethering donor DNA |
Country Status (10)
Country | Link |
---|---|
US (2) | US11339385B2 (en) |
EP (1) | EP3775239A4 (en) |
JP (1) | JP2021519101A (en) |
KR (1) | KR20210027244A (en) |
CN (1) | CN112154211A (en) |
AU (1) | AU2019244594B2 (en) |
CA (1) | CA3094906A1 (en) |
IL (1) | IL277549A (en) |
SG (1) | SG11202009196QA (en) |
WO (1) | WO2019186348A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704033B1 (en) * | 2019-12-13 | 2020-07-07 | Inscripta, Inc. | Nucleic acid-guided nucleases |
CA3224970A1 (en) * | 2021-07-06 | 2023-01-12 | Holly A. REES | Compositions and methods for efficient genome editing |
CN113667017A (en) * | 2021-07-28 | 2021-11-19 | 上海南方模式生物科技股份有限公司 | Method capable of improving homologous recombination efficiency of CRISPR/Cas9 system and application |
EP4399292A2 (en) | 2021-09-08 | 2024-07-17 | Flagship Pioneering Innovations VI, LLC | Methods and compositions for modulating a genome |
CN116083465B (en) * | 2023-01-03 | 2024-01-05 | 态创生物科技(广州)有限公司 | Lactose negative sensing plasmid and negative feedback lactose biosensor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102762726A (en) * | 2009-11-27 | 2012-10-31 | 巴斯夫植物科学有限公司 | Chimeric endonucleases and uses thereof |
AU2015330699B2 (en) * | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
WO2016183448A1 (en) * | 2015-05-14 | 2016-11-17 | University Of Southern California | Optimized gene editing utilizing a recombinant endonuclease system |
WO2017040511A1 (en) * | 2015-08-31 | 2017-03-09 | Agilent Technologies, Inc. | Compounds and methods for crispr/cas-based genome editing by homologous recombination |
US20170058272A1 (en) * | 2015-08-31 | 2017-03-02 | Caribou Biosciences, Inc. | Directed nucleic acid repair |
-
2019
- 2019-03-25 CN CN201980033066.1A patent/CN112154211A/en active Pending
- 2019-03-25 SG SG11202009196QA patent/SG11202009196QA/en unknown
- 2019-03-25 CA CA3094906A patent/CA3094906A1/en active Pending
- 2019-03-25 EP EP19778174.3A patent/EP3775239A4/en not_active Withdrawn
- 2019-03-25 US US16/363,642 patent/US11339385B2/en active Active
- 2019-03-25 WO PCT/IB2019/052378 patent/WO2019186348A1/en active Search and Examination
- 2019-03-25 JP JP2020552895A patent/JP2021519101A/en active Pending
- 2019-03-25 KR KR1020207030560A patent/KR20210027244A/en active Search and Examination
- 2019-03-25 AU AU2019244594A patent/AU2019244594B2/en active Active
-
2020
- 2020-09-23 IL IL277549A patent/IL277549A/en unknown
-
2021
- 2021-11-19 US US17/531,450 patent/US20220325264A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021519101A (en) | 2021-08-10 |
IL277549A (en) | 2020-11-30 |
EP3775239A4 (en) | 2022-01-05 |
KR20210027244A (en) | 2021-03-10 |
AU2019244594B2 (en) | 2020-11-05 |
US11339385B2 (en) | 2022-05-24 |
US20190309275A1 (en) | 2019-10-10 |
AU2019244594A1 (en) | 2020-10-15 |
EP3775239A1 (en) | 2021-02-17 |
SG11202009196QA (en) | 2020-10-29 |
WO2019186348A1 (en) | 2019-10-03 |
CN112154211A (en) | 2020-12-29 |
CA3094906A1 (en) | 2019-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220325264A1 (en) | Modified nucleic acid editing systems for tethering donor dna | |
CN110891420B (en) | CAS transgenic mouse embryonic stem cell, mouse and application thereof | |
US20210261985A1 (en) | Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo | |
US20240301442A1 (en) | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus | |
JP2024099582A (en) | Compositions and methods for transgene expression from the albumin locus | |
KR20210102882A (en) | Nucleic acid constructs and methods of use | |
US20190032156A1 (en) | Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo | |
AU2020289581A1 (en) | Non-human animals comprising a humanized albumin locus | |
CN114746125A (en) | CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy | |
CN117178959A (en) | Non-human animals comprising a humanized clotting factor 12 locus | |
WO2020092725A1 (en) | Gene modulation with crispr system type i | |
RU2782356C2 (en) | Methods and compositions for assessment of mediated crispr/cas destruction or cutout and induced crispr/cas recombination with exogeneous donor nucleic acid in vivo | |
KR20240133692A (en) | Mobility elements and chimeric constructs thereof | |
CN118660959A (en) | Moving element and chimeric constructs thereof | |
WO2023081814A2 (en) | Mobile elements and chimeric constructs thereof | |
WO2023220654A2 (en) | Effector protein compositions and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENETETHER, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SARGENT, ROY GEOFFREY;REEL/FRAME:058608/0442 Effective date: 20190528 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |